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ABSTRACT
Bhana, Saheel. PhD. The University of Memphis. August, 2015.
Nanotechnology for the Capture, Detection, and Combinatorial Treatment of Cancer.
Major Professor: Xiaohua Huang. Ph.D.

Cancer is a major health problem worldwide and is the second cause of death in
the United States. Improved methods to fight cancer are greatly needed. The early
detection of cancer is vital to help stop the spread of cancer. Circulating tumor cells are a
hallmark of this invasive behavior of cancer. Sensitive and specific detection of CTCs
can help in early detection of cancer preventing metastasis. CTC detection is extremely
challenging because the number of CTCs in the blood of cancer patients is extremely
low. Here, we report a new assay for high sensitivity detection of rare epithelial cancer
cells in unprocessed blood based on innovative application of dually functional magneticoptical hybrid nanoparticles (NPs). We developed novel iron oxide-gold core-shell NPs
in oval shapes with combined superparamagnetic properties and SERS activities. The
NPs allow on-line magnetic separation and SERS detection of cancer cells in whole
blood, with the detection sensitivity down to 1-2 cells/ mL of blood. Our method provides
a simple, rapid, quantitative and ultrasensitive technique for CTC detection. Improvement
of current cancer therapies is also vital in the fight against cancer. Nanotechnology-based
photothermal therapy has emerged as a promising treatment for cancer during the last
decade. However, heterogeneous laser heating and limited light penetration can lead to
incomplete tumor cell eradication. Here, we developed a couple of methods to overcome
these limitations by using combinatorial therapy within a single nanoconstruct. We have
combined chemotherapy with photothermal therapy using paclitaxel (PTX)-loaded gold
nanorods. We have also combined photodynamic and photothermal therapy with silicon
ii

2,3 napthalocyanine (SiNC) loaded iron oxide cluster-gold nanoparticles. PTX and SiNC
were entrapped in the hydrophobic pocket of the polymeric monolayer on the surface of
the nanoparticles, which allows direct cellular delivery of the hydrophobic drugs via the
lipophilic plasma membrane. The paclitaxel-gold nanorod and SiNC- loaded iron oxide
cluster-gold nanopopcorn have the potential of preventing tumor reoccurrence and
metastasis and may have important impact on the treatment of head and neck cancer and
other malignancies in the clinic.
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PREFACE
This dissertation is based on 4 papers that have been published. Chapter 1 is
partly based on the review article "Nanotechnology for Enrichment and Detection of
Circulating Tumor Cells". This article is published in Nanomedicine. Chapter 2 is based
on the article, “Capture and Detection of Cancer Cells in Whole Blood with Magnetic
Optical Nanoovals” This article is published in Nanomedicine. Chapter 3 is based on
"Gold Nanorods Carrying Paclitaxel for Photothermal-Chemotherapy of Cancer". This
article has been published in Bioconjugate Chemistry. Chapter 4 is based on "NearInfrared Absorbing Gold Nanopopcorns with Iron Oxide Cluster Core for Magnetically
Amplified Photothermal and Photodynamic Caner Therapy". This article has been
published in Applied Materials and Interfaces.
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Chapter 1. Introduction
1.1. CANCER DETECTION
Cancer is a major health problem worldwide. In the United States, cancer is the
second cause of death, with 1,658,370 new cases and 589,430 deaths estimated to occur
in 2015 1. Metastasis is the major cause of death in cancer patients, accounting for about
90% of the mortality 2. Although the mechanism of metastasis is not fully understood, it
is known that a mandatory step of the metastatic cascade is the transport of tumor cells
that are shed from the primary tumor site throughout the bloodstream of cancer patients 3.
During transport, a small population (<0.01%) of these circulating tumor cells (CTCs)
arrests in a capillary bed at a distant site where they extravagate and seed the growth of a
secondary tumor. The clinical value of CTC detection remains to be learned, but many
studies have shown their great potential 4. It has been realized that detection and
characterization of CTCs may provide a non-invasive liquid biopsy for characterizing and
monitoring cancer 5. The prognostic significance of CTC detection has been
demonstrated in several types of cancers including breast, prostate, colon, melanoma and
lung cancer 6-10. CTCs are also useful in monitoring and predicting the response to
ongoing therapy 11-13. In addition, detection of CTCs shows strong promise for early
cancer detection since they have been found in blood during early stages of tumorigenesis
14

. Furthermore, molecular profiling of CTCs may offer insights into mechanisms of

cancer progression and provide new therapeutic targets 15.
CTC detection and analysis, however, are very challenging 16. The major
challenge is that CTCs are rare events, as few as one CTC mixed with about 10 million
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white blood cells (WBCs) and 5 billion red blood cells (RBCs) in 1 mL of blood of
metastatic patients 17. Another key challenge is that CTCs are heterogeneous in
population due to tumor heterogeneity and potential changes of molecular characteristics
during the epithelial to mesenchymal transition (EMT) 18. As a result, significant
advancement in this area has only been made in the last two decades, even though CTCs
were first discovered in 1869 19. To date, a vast number of isolation and detection
techniques have been developed, with about 100 companies offering CTC-related
products and devices and over 400 clinical trials ongoing 20. However, there is only one
technique that has been approved by The U.S. Food and Drug Administration (FDA) for
clinical utilization, the CellSearch system (Veridex, LLC) 17. This technique is used to
enumerate CTCs in patients with metastatic breast, prostate and colorectal cancer to help
inform clinical decision making 8.
Nanotechnology plays an important role in CTC enrichment and detection, with
boosted interests in recent years (Figure 1.1). Nanoparticles (NPs) are all around us in
nature and have been around forever, but only over the last few decades have the
experimental methods become available which allow chemists to synthesize
nanomaterials in a controlled and reproducible way.21 These nanomaterials, behave
significantly different than bulk materials due to their unique surface and quantum
confinement effects.22 These NPs display different physical and chemical properties
which have made them a major focus of research over the past decade. One major
application of the use of NPs is in biomedicine. The rationale for using nanoscale
materials, typically 1-100 nm, for bio-applications is they can easily integrate with
biological entities such as proteins (5-50 nm), viruses (20-500 nm), genes (2-100 nm),
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and other biological molecules because they are on a similar size scale.23 When linked
with targeting ligands, they can recognize CTCs with high specificity, allowing for
isolation, detection and characterization based on the functional properties of the
nanomaterials. Nanomaterials have a large surface-to-volume ratio, which enables highly
efficient cellular binding in the complex blood matrix. Nanomaterials can be readily
manipulated to allow multiplexed detection and analysis, which are very important to
address the heterogeneous problem of CTCs.

Magnetic separation
Enrichment
Nanostructured substrate
Fluorescent detection

Nanotechnology

Detection

Surface enhanced Raman
scattering detection
Magnetic detection
Electric detection

Dual enrichment and detection

In vivo enrichment and detection

Figure 1.1. Schematic diagram showing nanotechnology applications in CTC enrichment
and detection.
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CTC Enrichment.
CTC detection and analysis are usually performed ex vivo using blood samples
collected from cancer patients. Due to the rarity of CTCs, an initial step is often needed to
isolate and enrich the tumor cells from a sufficient amount of blood. Current enrichment
methods can be divided into two categories: those based on physical properties such as
size, density, deformability, adhesion, and dielectric properties, and those based on
biological properties such as protein expressions 24. Classic approaches in the former
category are density gradient centrifugation, membrane filtration and microchip-based
capture platforms. Approaches in the latter category include magnetic separation,
substrate- and microchip-based capture platforms. The most commonly used marker for
CTC recognition is epithelial cell adhesion molecule (EpCAM). Since epithelia cells are
not usually found in circulation, the findings of EpCAM-positive cells indicate the
presence of CTCs. Nanomaterials are usually utilized in approaches based on biological
properties.
Magnetic nanoparticles.
Magnetic nanoparticles (MNPs), commonly composed of magnetic elements such
as iron (Fe) and cobalt (Co) and their chemical compounds, show alignment of their
magnetic moment in the presence of magnetic field. This magnetic alignment eventually
pins down in the same direction of the external magnetic field under saturation 25.
Depending on the particle size, shape and composition, the magnetic response of NPs can
have two different behaviors, ferromagnetic and superparamagnetic (Figure 1.2A) 26.
Ferromagnetic NPs show a remnant magnetization after removal of the field, while
superparamagnetic NPs do not have a remnant magnetization due to thermal fluctuations.
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The magnetic response causes the movement of the NPs in the direction of applied
magnetic gradient and thus the MNPs are separated from the resting solution.
Magnetic separation using magnetic particles is one of the leading CTC enrichment
methods 27. This method is easy to manipulate and exhibits high capture efficiency and
specificity. Captured cells can be easily recovered by removing the magnetic field. The
particles can be either microbeads (> 0.5 m) that are generally made of polymeric
matrix with embedded magnetic materials, or MNPs (5-200 nm). Due to the size
difference, MNPs have several distinct advantages over microbeads. MNPs have higher
cellular binding capability and excellent stability in whole blood. Thus, they can be used
for CTCs detection in whole blood sample, avoiding blood pre-treatments. In addition,
the small size of NPs allow many NPs to be attached to a cell without cell aggregation
resulting in higher magnetic susceptibility 28. Furthermore, the NPs allow for multiplexed
detection by using different sized NPs or NPs labeled with different detection tags.
Bulk magnetic separation
Classical magnetic separation is done with the use of an external permanent
magnet, usually neodymium-iron-boron (NdFeB) magnet, to attract MNP-bound CTCs in
a bulk solution under a stationary condition (Figure 1.2B). When the targeted cells are
bound with MNPs, the magnetic attraction toward the magnetic field gradient causes the
separation of the cells from non-targeted components. The magnetic force is proportional
to the number of bound NPs 29. Thus, under the same magnetic field, the NP-bound cells
are isolated much faster than free NPs and thereby selectively enriched. The FDAapproved CellSearch system is based on this approach to enrich CTCs using 120-200 nm
Fe NPs (ferrofluid) linked with anti-EpCAM antibodies 30. In combination with
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immunofluroescence detection targeting cytokeratin, the system reaches over 80 %
recovery rate of spiked breast cancer cells 31. Although the CellSearch system is currently
the gold standard to detect CTCs, a major limitation is that it only captures and detects
EpCAM-positive cells. EpCAM expression is often heterogeneous in cancer cells and its
downregulation has also been correlated with CTCs in peripheral blood 18. This may
explain why up to 70% patients known to have metastatic disease failed to exhibit
detectable CTCs using the CellSearch system 32.

(A)

(B)

N

MNP

RBC

WBC

CTC

S

Other non-CTC cells

Figure 1.2. MNPs for magnetic enrichment of CTCs. (A) Ferromagnetic and
superparamagnetic properties of MNPs. Reproduced from ref 26 with permission of The
Royal Society of Chemistry. (B) Schematic of bulk magnetic separation under a
stationary condition.

Microchip-based magnetic separation.
Microfluidic devices have become one of the mainstream platforms for CTC
enrichment and detection due to many advatanges including miniturization, portablility,
cost-effectiveness and the abilities of on-line isolation/detection and single cell analysis
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33

. Many novel microchip platforms have been developed based on affinity, size or other

physical properties 34. A new direction in immunomagnetic separation is to perform the
separation on a microfludic device. This microchip-based magnetic separation has the
benefits of both immunomagnetic separation and microfluidic device. Under the flow
condition, the capture efficiency dependes on the ratio of magnetic force and drag force
35

. The magnetic force is proportional to the number of bound particles on the cell. Thus,

a cell with many bound NPs has a large ratio of the two forces and can thus be captured.
The free NPs are more effectively removed by flow drag forces.Cell isolation in the
microfluidic channels is often performed with permanents magnets under the chip 35-41
The capture efficiency and sample throughput can be precisely controlled through the
design of the fluidic channels, the control of the flow rate, and the magnetic field
strength.
Zhang and co-authors have extensively studied both experimentally and
theoretically the effects of these parameters on the tumor cell capturing efficiency 35,39,40.
They showed that over 85% spiked cancer cells in blood can be captured with EpCAM
targeted Fe3O4 NPs at a speed of 10 mL/h-1 using NdFeB block magnets with a
maximum energy product of 42 MGOe [46]. They also showed that the performance of
the separation can be improved by inverting the microchannel (magnet placed on top of
the channel)

40

In this mode, the direction of the gravity is opposite to that of the

magnetic field force. Thus, the effects of RBC sedimentation on CTC catpure is greatly
reduced. Using the inverted microchip-based immunomagnetic separation with Fe3O4-Au
core-shell NPs, Sokolov and co-authors demonstrated that CTC capture efficiency can be
markedly improved by duplex targeting 41. For example, when SK-BR-3 cells are
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incubated with a mixture of anti-EpCAM conjguated and anti-HER2 conjguated NPs, cell
capture efficiency was improved by 24% as compared to the single targeting strategy
with EpCAM only.
In some devices, the microfluidic channels are structurally designed to facilitate
or enhance cell capture 42-45. For example, the device reported by Chen et al. contains an
array of magnetic microposts fabricated inside the channel to generate a strong magnetic
force when magnetized by the external permanent magnet 45 .Unlike most reported
microchip-based methods, the external magnetic field is applied in a parallel direction to
the flow, which reduce the effects of hydrodynamic force on cell capture. Validation
studies showed that the device can capture 90% spiked tumor cells labeled with antiEpCAM conjugated ferrofluid NPs at a flow rate of 6 mL/h with anti-EpCAM conjugated
Fe NPs. To improve sample throughput and capture efficiency, Earhart et al. recently
developed a magnetic shifter device, composed of an array of 40 um holes in a silicon
nitride membrane and a 12 um thick coating of a magnetically soft permalloy 46. Due to
the extremely high field gradients at the pore edges and high density of pores (~200
pores/mm2), the magnetic microfilter combined with anti-EpCAM conjugated MNPs, can
capture 96% spiked cancer cells in blood at a flow rate of 10 mL/h.
Nanostructured substrates
The past few years have witnessed the emergence of nanostructured substrates as
a new platform for capturing and enriching CTCs 47,48. When the substrates are
functionalized with targeting ligands, CTCs are captured on the substrate through ligandantigen binding. Compared to flat substrates, the major advantage of the nanostructured
ones is the enhanced local topographic interactions between the substrates and targeting
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cell surface, which results in vastly enhanced cell capture affinity 49. In addition,
nanostructures can be coated with ligands with much higher densities than flat surfaces
and thus can introduce multivalent effects to improve binding affinity. Furthermore,
when the nanostructures are embedded into a microfluidic device, they lower the rolling
velocity of cells in microfluidic channels and thus further enhance cellular binding. Many
different types of nanostructured substrates have been fabricated for CTC enrichment,
including nanoarray 49-55, nanofiber 56,57, nanosheet 58,59, deposited NP substrates 60-62
roughened surface 63-66, and nanoporous substrates 66,67.
CTC Detection.
Following isolation and enrichment, CTCs are detected and analyzed using either
cytometric or nucleic acid-based approaches 67. While cytometric methods analyze the
cells based on protein expressions, the nucleic acid methods detect genetic alterations
specific to tumor cells. Cytometric methods include immunohistochemistry imaging,
spectroscopic detection and flow cytrometry. The advantage of using cytometric methods
over nucleic-acid based methods is the possibility to further characterize the cells since
cell lysis is not required in the former procedures. When CTCs are examined
microscopically, cell morphology can also been examined. Nucleic acid-based methods
can analyze genetic information on whole cell or extracted RNA or DNA using PCR, RTPCR, quantitative real-time RT-PCR, whole-genome amplification (WGA) and
fluorescent in situ hybridization (FISH) 68. In general, nucleic acid methods have high
sensitivity but low specificity due to interference from the expression of markers in
normal cells. In general, nucleic acid methods have high sensitivity but low specificity
due to the expression of markers in normal cells. Nanomaterials are used in a variety of
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detection methods by taking advantages of their unique functional properties. Based on
the mechanism of signal readout, one of the major types of nanomaterial used in this area
is optical NPs.
Optical Nanoparticles.
Fluorescence is a leading technique for CTC detection and analysis. Generally, it
is done with organic dyes as the imaging agents. However, it has been widely realized
that the use of organic dyes is limited by photobleaching, low signal intensity, spectral
overlapping and the need for multiple light sources to excited different fluorophores in
multiplexed detection. Alternatively, Quantum dots (QDs) have large absorption
coefficient, narrow emission, high photostability and superior brightness 69. Their
emission can be precisely tuned by changing the size and composition of the NPs, which
results in multicolor NPs with a single excitation laser source 69. Due to these excellent
properties, they have been widely used in biomedical imaging during the last decade 70.
However, they have not attracted much attention in CTC imaging 71-73. The major
concern is their cytotoxicity that may cause cell molecular changes and damage 74. To
avoid the toxicity issue, QDs can be used to detect CTCs by monitoring extracted nucleic
acids. An example is the microfluidic bead-based nucleic acid sensor developed by
Zhang et al. using multienzyme-nanoparticle amplification and QD labels 75. By
measuring the fluorescence signal intensity from QDs, the amount of targeted DNA can
be quantified. The method can detect 1 spiked colorectal cancer cell in the blood.
Surface enhanced Raman scattering nanoparticles.
Due to the strong surface electromagnetic fields that propagate around metallic
NPs, molecules in close proximity to the surface of these NPs may also exhibit enhanced
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properties.76 An example of this plasmonic near-field effect is the large enhancement of
the Raman scattering of light by molecules adsorbed onto the surface of the NPs. In
Raman spectroscopy a strong, monochromatic, visible wavelength light
source is used to excite a molecule to a virtual state. The vast majority of these excited
molecules then scatter this light as elastic Rayleigh scattering at the same frequency.77
However, a small portion of these molecules will undergo a change in vibrational state
during relaxation to the ground electronic state, resulting in scattered light of a different
frequency than that of the incident photons 77. This inelastic scattering of light was first
discovered by the Indian physicist C.V. Raman in 1928 78. Typically the scattered light is
of a lower frequency than the incident photons which is known as Stokes Raman
scattering. It is also possible for molecules to be excited from an excited vibrational state,
and then to return to a lower vibrational state, (the ground vibrational state), emitting a
photon with a higher frequency than that of the incident photon know as anti-Stokes
Raman scattering. This is less probable due to the lower population of molecules in
higher vibrational energy levels at thermal equilibrium. The main difficulty in normal
Raman spectroscopy is the low yield of Raman scattered photons, approximately 1 in 107.
Therefore although Raman spectroscopy has become a promising analytical tool, the
method requires increased sensitivity.
One of the most promising methods in enhancing the Raman scattering is known
as surface enhanced Raman scattering (SERS). SERS was first discovered in 1974 by a
group led by James A. McQuillan when they observed enhanced Raman signals from
pyridine adsorbed on a silver electrode 79. Optical NPs, in particular Au NPs, are
desirable substrates for SERS-based biomedical detection because of their facile
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synthesis and excellent biocompatibility. Raman reporters (organic dye molecules highlydelocalized pi electrons) are readily adsorbed or covalently conjugated to the metal NPs.
This results in a strong SERS signal that is specific to the attached Raman reporter. The
dye-adsorbed metal NPs, termed surface enhanced Raman scattering nanoparticles (SERS
NPs), have emerged as a new generation of optical labels for biomedical imaging and
diagnosis 80-86. Different from the fluorescence technique, SERS gives sharp fingerprintlike signals (10-100 times narrower than fluorescence signals), distinct from biological
autofluorescence/scattering background. The enhancement of the Raman signal can be as
high as 1014 therefore proving to be very advantageous in ultra-sensitive assays.87 Raman
reporters have been used to detect different biomarkers in cancer, viral and bacterial
microorganisms and other diseases.88-90 Raman reporters have recently been used as a
tool for the detection of CTCs.91
In 2008, Sha et al. demonstrated for the first time the potential of SERS NPs for
CTC detection using spiked breast cancer cells 92. 50 nm Au SERS NPs (Nanoplex
Biotags) are linked with HER2 antibodies to target SK-BR-3 cells. By coupling with
immunomagnetic enrichment with anti-EpCAM conjugated magnetic beads, the method
can detect 10 tumor cells per mL blood. The studies used a sample holder with a
magnetic assembly that focuses the tumor cells on a precise location on the wall of the
tube for detection. A recent modified strategy was to magnetically enrich the labeled cells
in a tube under a flow condition, followed by the detection by SERS technology 93. The
flow condition can be facilely translated into microfluidic modality for single cell
analysis.
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In 2011, Wang et al. developed a SERS-based assay using Au NPs covalently
linked with epidermal growth factor (EGF) peptide in combination with density gradient
centrifugation enrichment and tested the assay with patient blood samples91. QSY21
quencher was used as the Raman reporter. The method can detect 5-50 spiked head and
neck cancer cells in blood. Studies on clinic blood samples showed that CTCs in 17 out
of 19 patients with head and neck cancer were detected, with CTC number ranging 1 to
720. A major advantage of this methodology is the specific detection of CTCs in the
presence of WBCs, due to the use of small EGF peptide rather than whole antibody
ligands.
Recently, Zhang demonstrated the use of SERS NPs for CTC detection and
enumeration at single cell level by combining a membrane substrate-based enrichment 94.
Nitrocellulose membrane substrate were functionalzed with anti-EpCAM antibodies to
capture CTCs. The captured CTCs were labeled with Au SERS NPs linked with EpCAM
antibodies. Microscopic SERS imaging was performed to detect and count CTCs. A
significant advancement was made in the same year by Nima et al. who applied SERS
for multicolor CTC imaging 95. In their studies, 4 color SERS NPs were formed using
Ag-coated Au nanorods (NRs) and four different Raman reporters (Figure 1.3). Each
color NP was linked with specific antibodies to target one of the four markers on breast
cancer cells, insulin growth factor 1 (IGF-1), anti-EpCAM, anti-CD 44 and anti-keratin
18. Using the SERS probe cocktail and the signature SERS peak from each reporter, the
four markers on the same cell were imaged with a confocal Raman microscope. This
represents a significant advancement in developing SERS-based technologies for CTC
detection and analysis.
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Figure 1.3. NPs for multiplexed detection, imaging and profiling of CTCs.
Multiplexed imaging of CTCs using 4 color Au-Ag core-shell SERS nanorods. Left:
Absorption and TEM image of Ag-Au core-shell nanorods. Red: Au nanorods. Black:
Au-Ag core-shell nanorods. Middle: Preparation and SERS spectra of 4 color Au-Au
SERS nanoprobes. Right: Raman imaging of tumor cells with 4 color Au-Au SERS
nanoprobes 95. Reprinted by permission from Macmillan Publishers Ltd: [Science
Reports] (ref 95), copyright (2014).

In vivo enrichment and detection with nanomaterials.
Techniques capable of detecting and quantifying CTCs in vivo are valuable
because they are noninvasive and can monitor CTC level in real-time. They detect CTCs
in the entire blood volume of the body, which can enhance sensitivity up to 102-103 times
as compared to ex vivo methods 96. In vivo CTC detection has been done on superficial
vessels with a mouse model by in vivo flow cytometry using traditional fluorescence 97101

or newly developed photothermal (PT) and photoacoustic (PA) 102-106 detection

methods, or a combination of these methods 107,108.
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1.2. CANCER THERAPY
Along with the detection of CTCs, the development of more effective cancer
treatment methods is urgently needed to increase the overall survival of cancer patients.
One of the more promising cancer treatments is phototherapy. Phototherapy is a type of
treatment that uses light and includes two major modalities, photodynamic therapy (PDT)
and photothermal therapy (PTT). Another major type of cancer therapy is chemotherapy,
which involves the use of medicine and drugs to combat cancer.
Photothermal Therapy.
Photothermal therapy is currently one of the most promising research applications
in the treatment of cancer and other diseases 109. Photothermal therapy (PTT) is a type of
cancer treatment in which light energy is converted into heat via nonirradiative processes
to destroy cancer cells and tumor tissues 110-112. It is advantageous over other methods
because they are noninvasive, localized, portable, inexpensive, simple to operate and
provide rapid results. Traditionally, photothermal dye molecules such as indocyanine
green and naphthalocyanines were added to enhance the treatment 111. However, these
photothermal agents are subjected to photobleach under laser irradiation, rendering low
therapeutic efficacy.
During the last decade, near infrared (NIR)-absorbing gold nanoparticles (NPs)
such as: silica/gold nanoshells 113-117, gold nanorods (Au NRs) 118-122, gold nanocages and
hollow gold nanospheres 123-125 have emerged as new generation of photothermal agents
because of their excellent nonradiative photothermal properties in the tissue penetration
NIR window (650-950 nm) where light penetration is optimal due to minimal absorption
by water and hemoglobin in the tissue 126. When these metallic NPs are exposed to laser
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light in resonance with their surface plasmon oscillation, they have the ability to strongly
absorb the light and rapidly convert it into heat via a series of photophysical processes 127.
Metallic NPs, in particular Au NPs, have many advantages including: a strong absorption
due to their high molar absorptivity (108-9 M-1 cm-1) ,128 higher solubility, efficient
absorption in NIR window, and facile conjugation with targeting molecules and drugs.
These properties make Au NPs the most promising candidates for photothermal therapy
of cancer and various pathogenic diseases 127.
Various types of Au NPs have been used for photothermal ablation of cancer cells
and various other diseases 120,127. El-Sayed et al. first demonstrated the use of gold
nanorods for in vivo photothermal therapy in 2008, showing that the method was able to
significantly inhibit tumor growth following a single 10 minute laser exposure
experiment 119. Gold nanorods have also been shown to ablate tumors in mouse models
of colon cancer and squamous cell carcinoma 119. Xia et al. used targeted gold nanocages
approximately 45 nm in length and with plasmonic absorption maxima at 810 nm, to
ablate SK-BR-3 breast cancer cells in cell culture studies 129. With the use of PEG-coated
gold nanorods injected at tumor sites of mice, Bhatia et al. were able to use X-ray
computed tomography as a guide for photothermal therapy with high efficacy due to the
optical properties of gold nanoparticles 130.
Despite the advancement of PTT by the use of NIR-absorbing Au NPs, it remains
difficult to completely eradicate tumor cells. This is because NP distribution in tumors is
heterogeneous, which leads to heterogeneous heat production. Especially, NPs are mainly
confined to the perivascular regions of tumors due to the high hydrostatic pressure with
tumors and slow diffusion of the large particles. Furthermore, the amount of NPs in
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tumors delivered by classic enhanced permeability and retention effect (EPR) remains
limited. Thus, it is highly desirable to develop strategies to improve the efficacy of PTT.
Photodynamic Therapy.
Photodynamic Therapy (PDT) is another therapeutic approach that has emerged
for the treatment of cancer. It involves a combined effect of a photosensitizer and a
noninvasive light dose with an appropriate wavelength that matches the excitation of the
photosensitizer. In PDT, a photosensitizer (PS) absorbs light energy and is then excited
from ground state to a high energy state which transfers energy to neighboring oxygen,
leading to production of high energy reactive oxygen species (ROS) mainly singlet
oxygen (

1

O2

) to kill cancer cells 131-133. As the treatment is noninvasive, localized,

portable, inexpensive, and simple to operate, it has received considerable attention for
many years and used in the clinic for the treatment of certain cancers such as esophageal
cancer and non-small cell lung cancer 134. There has been much success using PDT as a
cancer treatment in clinical settings 135-137. However, conventional PDT is limited by the
poor water-solubility and non-specificity of most PSs as well as the inherent
photobleaching issue of the PS agents. To improve the delivery efficiency and tumor
specificity, substantial efforts have been made on the development and use of
nanocarriers during the past decades 138,139.
Among the various types of PS carriers, photothermal (PT) NPs show strong
promises 140-154. This is because cancer cells can not only be destroyed by PDT via the PS
molecules, but also photothermal therapy through the photothermal NP carriers. For deep
tissue penetration, the NPs require light absorption in the transparent near infrared (NIR)
window. Graphene oxide 140-143, gold nanorods (Au NRs) 144-151, and some other NIR-

17

absorbing NPs and nano-assemblies 152-154 have been used as PS carriers to enable dual
mode PDT and PTT. In particular, Au NRs have attracted a great deal of attention
because of several advantages: (1) Compact size (around 50 nm in length), (2) ease of
preparation, (3) excellent stability (shelf life more than one year), and (4) long circulating
property, with the half-life more than 10 h when modified with poly (ethylene) glycol
(PEG) 155,156.
Although PDT has achieved some success, it is without its own limitations as many of the
photosensitizers require the excitation of light that limits its penetration into tissue, thus
confining its treatment to superficial regions 157.
Chemotherapy.
Conventional chemotherapy employs drugs that are known to kill tumor cells
effectively by targeting the proliferation potential and metastasizing ability of the cells.
Despite the progress made in the development of these cytotoxic drugs, their toxicity to
healthy cells, in addition to tumor cells, leads to adverse side effects such as: nausea,
neuropathy, hair-loss, fatigue, and compromised immune function 158. The use of NPs as
drug carriers for chemotherapeutics have become a promising approach to deliver
medication directly to the tumor which in turn spares healthy tissue . Due to the leaky
vasculature of tumor cells, the enhanced permeability and retention (EPR) effect leads to
the preferential accumulation of NPs at the tumor sites 159. Au NPs are a useful tool for
the delivery of the drugs to cellular destinations due to their ease of synthesis,
functionalization and biocompatibility. Another advantage of using Au NPs for drug
delivery is their capability for bioimaging due to their strong optical properties. Drugloaded Au NPs have also showed enhanced pharmacokinetics and tissue accumulation
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compared to free drugs 160. Recently, paclitaxel, (PTX), an anticancer drug, was loaded
onto gold nanorods with a high density (2 x 104 PTX/Au NR) via a facile, fast, and highly
efficient method. The drug was efficiently released to exert cytotoxic effects via
hydrophobic interactions of the drug and apolar lipid membrane 161. Multimodal delivery
systems can also be used, where Au NPs are loaded with several drugs (hydrophilic and
hydrophobic) as well as target molecules to ensure better delivery to the target cell and
also help anchor the drugs 127. Au NPs are also excellent delivery vectors for substances
such as antibiotics and other antibacterial agents. Gu et al. have prepared a stable
vancomycin–colloidal gold complex and showed its effectiveness toward various
(including vancomycin-resistant) enteropathogenic strains of Escherichia coli,
Enterococcus faecium, and Enterococcus faecalis 162.
Au NPs offer many applications in biomedicine due to their unique chemical
properties such as excellent ability to absorb and scatter light, ability to transfer light
energy as heat, facile surface modification, and biocompatibility.
1.3. MOTIVATION
Circulating tumor cells (CTCs) can provide a potentially non-invasive liquid
biopsy for characterizing and monitoring cancer in order to help inform clinical decision
making. Although a variety of techniques have been developed to enrich and detect CTCs
during the last two decades, detection sensitivity and specificity remain key issues to be
addressed in future technologies. The dual functional nanomaterials such as magneticoptical core-shell nanoparticles are very promising to reduce false negatives by bridging
current enrichment and detection methods. In Chapter 2 we developed a model for the
dual capture and detection of CTCs in whole blood using novel magnetic-optical hybrid
19

surface enhanced Raman scattering NPs. The method is advantageous due to the
reduction of false negatives by bridging the enrichment and detection process. The
method also provides ultrasensitive detection via SERS technology. Our method provides
a promising model for developing a simple, rapid, quantitative and ultrasensitive
technique for rare cell detection, which could make an important impact in the field of
cancer medicine The detection and enumeration of CTCs via our integrated system is
discussed in this chapter.
One of the major challenges in cancer treatment is the specific accumulation of
photo-responsive agents/chemdrugs at tumor sites to achieve effective treatment without
toxicity to normal tissues. Nanotechnology has emerged as one of the most auspicious
methods to address this challenge 163-166. In Chapter 3 we have developed a new single
particle drug delivery system for the combined PTT-chemotherapy of cancer. Here we
have used Au NRs as the PT agent loaded with paclitaxel as a chemotherapeutic agent.
The combined treatment had a synergistic effect leading to complete eradication of
cancer cells in vitro at a certain dosage. The resulting nanocomplex may prevent tumor
regrowth and metastasis and have important impact on the treatment of head and neck
cancer in the clinic. In this chapter the synthesis, characterization, and cell viability of the
nanocomplex is discussed.
Chapter 4 we have synthesized and used of a new type of nanoplatform for
combined cancer PTT and PDT. Here, we have developed iron oxide cluster-gold
nanopopcorns with strong NIR absorption. Compared to existing PTT and PDT
nanosystems, our system has the potential to deliver both PDT and PTT agents deep into
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tumor via magnetic field-guided delivery. The characterization of the novel nanocomplex
along with its potential for cell therapy are studied in this chapter.
Chapter 5 will summarize the overall conclusions that are drawn from this
dissertation. A discussion on the future outlook will also be provided in this chapter. This
will include further improvements and additions to the current work.
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Chapter 2. Capture and Detection of Cancer Cells in Whole Blood with Magnetic
Optical Nanoovals
2.1. INTRODUCTION
Circulating tumor cells (CTCs) are malignant cells that have exfoliated from a
primary tumor and circulate in the bloodstream of cancer patients. They are a hallmark of
invasive behavior of cancer, responsible for the development of metastasis167. Their
detection can provide a powerful tool for cancer prognosis, assessment of tumor stage,
monitoring of therapeutic response and ultimately aiding in optimization of personalized
treatment for patient with metastatic cancer168. In addition, CTCs have been found in
blood during early stages of tumorigenesis169. Therefore, sensitive and specific detection
of CTCs can also help in early detection of cancer, thus enabling the prevention of
metastasis.
CTC detection, however, is extremely challenging because the number of CTCs
in the blood of cancer patients is very low, as few as one cell per 10 million leukocytes
(white blood cells) and 5 billion erythrocytes (red blood cells)169. It requires highly
specific and sensitive techniques to identify and capture rare cancer cells with high
efficiency. Over the last two decades, a variety of enrichment and detection techniques
have been developed, making significant progress in CTC detection 67,68,170-172. A general
strategy, including the only technique approved by the US FDA for clinical utilization
(CellSearch® system; Janssen Diagnostics, NJ, USA) 31, is to initially separate the tumor
cells from abundant blood cells using isolation methods such as density gradient
centrifugation, size-based filtration and immunomagnetic separation. After purification,
CTCs are collected, processed and analyzed based on nucleic acid- or protein-based
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tumor markers. Consequently, multiple procedural preparations are needed, often leading
to the loss of these rare cells and the decay of molecular biomarkers. In addition,
substantial human intervention, high cost and long turnaround times are also significant
barriers.
Dye-adsorbed metal nanoparticles (NPs), referred to as surface-enhanced Raman
scattering (SERS) NPs, have emerged as a new type of biological label for cancer
detection over the last decade 80,82,173-176. The rationale is that SERS NPs have exceptional
detection sensitivity and specificity. The enhancement of the Raman signals of the dye by
the supporting metal NPs can be as much as 1014–1015 87,177, thus facilitating the detection
down to the single molecule or single particle level. In contrast to the fluorescence
technique, SERS provides sharp fingerprint signals that are specific to the adsorbed
Raman reporters, allowing molecular detection in complex biological milieu. In 2008,
Sha et al. reported the use of gold (Au) SERS NPs in combination with magnetic beads to
detect CTCs in whole blood using CTC-mimic breast cancer cells, with a limit of
detection (LOD) of 50 cells/ml of blood 92. Recently, Wang et al. reported the detection
of head and neck cancer cells in the presence of white blood cells, using SERS Au NPs
and density centrifugation, with a LOD of 5-50 cells per mL of blood 178. The lack of
magnetic properties of current SERS NPs for CTC detection requires that additional steps
be taken to isolate and enrich the rare tumor cells. Correspondingly, additional magnetic
particles or other separation techniques such as density centrifugation have to be used in
order to isolate and enrich the rare tumor cells from abundant blood cells. This leads to
limited detection sensitivity because of the cell loss during multiple sample preparations.
In addition, magnetic particles currently used for CTC isolation are mainly micron-sized
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magnetic beads. Microparticles have a low surface-to-volume ratio, which leads to a
lower binding affinity compared to NPs. Microparticles are more likely to aggregate or
precipitate in whole blood due to gravitational sedimentation. In addition, microparticles
are not efficient for cell separation in whole blood because the high viscosity and high
cell density of blood milieu prevent efficient particle contact with the cell surface
receptors. Thus, pre-treatment of blood samples such as dilution with buffers,
centrifugation to separate plasma, and lysis of the red blood cells is generally needed to
increase the binding capability of the beads to cell surface antigens.
Here we report a new assay for high sensitivity detection of rare epithelial cancer
cells in unprocessed blood, based on innovative application of dually functional
magnetic-optical hybrid NPs. We developed novel iron oxide-gold (IO-Au) core-shell
NPs in oval shapes with combined superparamagnetic properties and SERS activities.
The highly integrated IO-Au SERS NPs allow on-line magnetic separation and SERS
detection of cancer cells in whole blood, with the detection sensitivity down to 1-2 cells
per mL of blood. Our method provides a huge step forward in developing a simple, rapid,
quantitative and ultrasensitive technique for CTC detection, which will make an
important impact in the field of cancer medicine.
2.2. MATERIALS AND METHODS
Reagents.
All chemicals were purchased from Sigma-Aldrich unless specified. QSY21was
purchased from Life Technologies (Grand Island, NY, USA). Anti-epithelial cell
adhesion molecules (anti-EpCAM) and anti-human epidermal growth factor receptors
(anti-HER2) monoclonal antibodies were purchased from AbCAM (Cambridge, MA,
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USA). Carboxy-poly(ethylene)-thiol (HOOC-PEG-SH, MW 5000) and methoxy-PEGthiol (mPEG-SH, MW 5000) were purchased from Laysan Bio, Inc (Arab, AL, USA).
SK-BR-3 cells were purchased from ATCC (Manassas, VA, USA). Human whole blood
was purchased from Research Blood Components, LLC. IO NPs (SHP 25) were obtained
from Ocean Nanotech (Springdale, AR, USA).
Synthesis and characterization of IO-Au nano-ovals (NOVs).
IO-Au NOVs were synthesized using a seed-mediated growth method 179 with
modifications. Firstly, 10 µL of 10 mM diamminesilver ions (Ag(NH3)2+), which were
prepared by mixing ammonia with silver nitrate (AgNO3), were added to 100 µL of 1
mg/mL negatively charged polymer-coated IO NPs and stirred for 30 min. The Ag+adsorbed IO NPs were purified by centrifugation (10,000 rpm, 8 min) and reconstituted
with 0.25 mL water, followed by addition of 100 µL of 10 mM sodium borohydride
(NaBH4) to form Ag-decorated IO NPs. After 40 min, the Ag-decorated IO NPs were
purified by centrifugation and three washings, and redispersed in 500 µL water.
Secondly, 1.5 mL of growth solution containing 0.4 mM chloroauric acid (HAuCl4), 0.1
M cetyl trimethylammonium bromide (CTAB) and 0.08 mM AgNO3 were prepared,
followed by addition of 23 µL of 40 mM ascorbic acid (AA). Then, 22 µL of the Agdecorated IO NP solution was injected and the solution changed to a purple color within a
few minutes, indicating the growth of IO-Au NOVs. The absorption spectra of the NPs
were measured using a VIS-NIR absorption spectrometer (Ocean Optics, Dunedin, FL).
The magnetic properties were measured using a vibration sample magnetometer (Dexing
Magnets, China). The size and morphology of the NPs were examined with a
JEM1200EX II TEM (JEOL Ltd, Tokyo, Japan).
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Preparation and characterization of antibody-conjugated IO-Au SERS NOVs.
Firstly, 50 µL, 0.1mM QSY21 was added to 1 mL of 0.1 nM IO-Au NOVs (QYS
21/IO-Au = 50,000). The mixture was vortexed in the dark for 15 min to allow the
adsorption of the dye onto the NPs. This was followed by addition of 20µL, 0.05 mM
HOOC-PEG-SH (HOOC-PEG-SH/IO-Au = 10,000). The bifunctional PEG binds to the
surface of the NPs via Au-S bonds. After vortexing for 20 min, 10 µL of 0.05 mM
mPEG-SH (mPEG-SH/IO-Au = 5,000) was added to saturate the surface of the NPs. The
mixture was vortexed for 1 hr in the dark at room temperature. The functionalized IO-Au
SERS NOVs were centrifuged and washed 3 times (10,000 rpm, 10 min) to separate
unbound molecules. The NPs were redispersed in 100 µL of pH 5.5 2-(Nmorpholino)ethanesulfonic acid (MES) buffer for ligand conjugation. To conjugate antiEpCAM or anti-HER monoclonal antibodies to the IO-Au SERS NOVs, 3 mg 1-Ethyl-3(3-dimethylaminopropyl)carbodiimide (EDC) and 3 mg sulfo-N-hydroxysuccinimide
(sulfo-NHS) were added to 100 µL of 1 nM functionalized IO-Au SERS NOVs in pH 5.5
MES buffer. EDC and sulfo-NHS were used to facilitate the binding of -COOH groups to
subsequent amines by forming intermediates with the –COOH groups. The mixture was
vortexed for 15 min, followed by addition of 900 µL of PBS and centrifugation (10,000
rpm, 10 min). The NP pellet was resuspended in 200 µL of PBS, followed by an addition
of 50 µL of 0.2 mg/mL antibodies. The solution was vortexed for 2 hr at room
temperature and then stored at 4oC. Prior to use, the solution was centrifuged and washed
3 times, and the antibody-conjugated IO-Au SERS NOVs were resuspended in 100 µL of
PBS. Surface modification at each step was monitored by dynamic light scattering (DLS)
measurement with a Particle Size Analyzer (Brookhaven Instruments Corp, NY, USA).
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Construction of an integrated system for on-line cell isolation and detection.
The major components of the system were a syringe pump (New Era Pump
Systems Inc, Farmingdale, NY, USA), a quartz capillary (ID=100 m, OD=110 m), two
cylindrical neodymium–iron–boron (NdFeB) magnets (K&J Magnetics Inc, Jamison, PA,
USA ) and a portable Raman spectrometer (Enwave Optronics, Irvine, CA, USA). The
capillary was connected to the syringe with a plastic cap. The magnet-1 was 20 mm in
diameter and 25 mm in thickness, with a surface field of 4800 Gauss (G). Its function is
to separate and capture tumor cells with a high flow velocity ( 3 cm/s). The magnet-2
was 0.2 mm in diameter and 3 mm in thickness, with a surface field of 500 G. Its function
is to capture and confine the purified tumor cells at low flow velocity (< 0.5 cm/s) to a
fine region for SERS detection. It was fixed in a styrofoam holder. Both magnets were set
up on the motorized XYZ stage of the Raman spectrometer. The capillary was tightly
attached to the top side of the magnets. During cell capture and detection, the two
magnets were attached to the system one at a time. The Raman spectrometer has an
excitation laser with wavelength at 785 nm and adjustable power up to 250 mW. The
laser beam spot is 200 m at focus.
Cell culture and labeling.
Human breast cancer cells SK-BR-3 were cultured in RPMI 1640 medium with
10% fetal bovine serum (FBS) at 37 °C under 5% CO2. To label cells with the antibodyconjugated IO-Au NPs, 10,000 SK-BR-3 cells in 1 mL of PBS were incubated with 5 pM
anti-EpCAM/QSY21/IO-Au NPs and 5 pM anti-HER2/QSY21/IO-Au NPs for 30 min
with gentle vortexing at room temperature. The cells were purified by repeated
centrifugation and washing (1,500 rpm, 3 min). Unconjguated IO-Au SERS NPs were
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used as the control. The NP-treated cells were fixed with 4% paraformaldehyde. Cellular
binding was examined by dark field imaging with an Olympus IX71 inverted microscope.
Determination of capture efficiency.
To determine the capture efficiency of tumor cells by the magnet-1, SK-BR-3
cells were labeled with a cocktail of anti-EpCAM/IO-Au SERS NOVs and antiHER2/IO-Au SERS NOVs, as described above. 1 mL of PBS containing 10,000 prelabeled cancer cells were introduced into the flow system and pumped through the
capillary at a variety of flow velocities in the presence of magnet-1. Uncaptured cells
were quantified by cell counting with a hemocytometer. To determine the capture
efficiency of the NPs by the magnet-1, 1 mL of 10 pM mPEG-stabilized IO-Au NOVs
was introduced into the flow system and pumped through the capillary at a variety of
flow velocities in the presence of magnet-1. The uncaptured NPs were quantified by
absorption spectroscopy. The capture efficiency of tumor cells or NPs was presented as
the percentage of trapped cells or NPs with respective to the loaded tumor cells or NPs.
Detection of pre-labeled SK-BR-3 cells spiked into whole blood.
SK-BR-3 cells were dispersed in PBS and labeled with a cocktail of 5pM antiEpCAM/QSY21/IO-Au NOVs and 5 pM anti-HER2/QSY21/IO-Au NOVs as described
above. After purification and fixation, the cells were resuspended in PBS and counted
with a hemocytometer. The cells were subject to a series of dilutions with PBS or human
whole blood to make 1mL solutions containing 10, 20, 50, 100, 250 and 500 cells. The
sample was transferred to a 1.0 mL syringe and placed on the syringe pump. With the
magnet-1 in position, the solution was pumped at 6 cm/s. After 10 min when all the
solution was pumped, a vial containing fresh PBS was placed at the end of the capillary.
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100 µL of PBS was pulled from the vial to resuspend the purified tumor cells while the
magnet-1 was removed. Then, the magnet-2 was placed under the capillary and the tumor
cells were pumped through the capillary at 0.2 cm/s. After 30 min when all the solution
was pumped, the Raman spectrometer was turned on and the SERS spectrum was
collected in real-time (10 ms per spectrum). The position of the magnet-2 was adjusted so
that the tumor cells were all exposed to the laser beam, giving maximal signals. The
focus of the laser was further adjusted to optimize the SERS signals. PBS or whole blood
was used as the negative control. The SERS spectrum with maximal intensity for each
sample was used for quantitative studies. The spectrum was baseline corrected to subtract
the SERS background (broad continuum emission) using a multi-segment polynomial
fitting. The plot of SERS intensity at 1496 cm-1 versus the cell number was fitted linearly
using Origin 8. The limit of detection (LOD) was determined to be the cell concentration
required to give a signal equal to the negative control plus three times that of the standard
deviation of the negative control.
Detection of SK-BR-3 cells spiked into PBS and into whole blood.
1 mL of PBS or human whole blood containing 10, 20, 50, 100, 250 or 500 fixed
SK-BR-3 cells was incubated with 5 pM anti-EpCAM/QSY21/IO-Au NOVs and 5 pM
anti-HER2/QSY21/IO-Au NOVs for 30 min with gentle vortexing at room temperature.
The mixture was then transferred into the flow system and subjected to isolation and
detection using the procedures described above. PBS or whole blood containing the same
concentration of conjugated NOVs but not tumor cells was used as the negative control.
The plot of SERS intensity at 1496 cm-1 versus the number of SK-BR-3 cells was fitted
linearly using Origin 8 and the LOD was calculated as the number of cells that gave a
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signal equal to the negative control plus three times that of the standard deviation of the
negative control.
2.3. RESULTS AND DISCUSSION
2.3.1. Synthesis and properties of IO-Au NOVs.
Anisotropic NPs are known to give much stronger enhancement of the electric
field of incident light waves than spherical NPs 180. Additionally, Raman signals are
proportional to the electric field of the light. Correspondingly, anisotropic NPs are better
SERS substrates than spheres with similar size. We previously developed near infrared
(NIR)-absorbing IO-Au NPs in pin shapes with 35-fold higher SERS activities than the
conventional IO-Au nanospheres179. Although the NPs allow surface plasmon resonance
(SPR) excitation with the NIR laser, which benefits Raman enhancement, a potential
concern is their photothermal effect that could change the Raman signals of the adsorbed
reporters and damage cell structures. To overcome this limitation, we made anisotropic
NPs with SPR shifted away from the wavelength of the Raman excitation laser without
decreasing the SERS strength.
The hybrid NPs were made from negatively charged IO NPs (
Figure 2.1A) using the seed-mediated growth method described previously 179, but with 7
times lower amount of ascorbic acid in the growth solution. The TEM image shows that
the IO-Au NPs are in oval shapes, with an average size (100 particles) of 60 nm along the
long axis and 50 nm in short axis (
Figure 2.1B). The shell of Au was estimated to be 12 to 18 nm in thickness. The coreshell NPs exhibit a SPR peak at 590 nm (
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Figure 2.1C&D). The magnetic properties of the hybrid NPs were tested by the magnetic
separation with external permanent magnets and quantitative magnetization measurement
with a vibration sample magnetometer. When a permanent magnet was attached to a
plastic vial containing the NOV solution, the particles were isolated from the solution,
similar to the behavior of IO NPs (
Figure 2.1E&F). The remaining liquid became colorless, indicating that the NOVs were
indeed core-shell NPs. The magnetization measurement revealed that the hybrid NPs
were superparamagnetic, similar to the IO core. The saturation magnetization of the coreshell NPs was 8 emu/g, which was 6 times lower than that of the IO core. This is not
surprising because of the mass contribution from the diamagnetic Au that has a density 4
times higher than IO.
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Figure 2.1. Structure and properties of IO NPs and IO-Au NOVs. (A, C & E) IO
nanoparticles and (B, D & F) IO-Au NOVs are shown. (A & B) TEM micrographs;
(C & D) Absorption spectra; (E & F) Magnetization curves at room temperature and
magnetic separation with external permanent magnets. The IO-Au NOVs are, on average
60 nm along the long axis and 50 nm along the short axis, with the IO core being 25 nm
in diameter. They are superparamagnetic and have a surface plasmon resonance (SPR)
absorption at approximately 590 nm. emu: Electromagnetic units
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2.3.2. Preparation and cell labeling of antibody-conjugated IO-Au SERS NOVs.
Figure 2.2 shows the major steps for the preparation of antibody-conjugated IOAu SERS NOVs targeting tumor cells. We used breast cancer as a model for the proof-ofconcept studies. The NOVs were firstly coated with QSY21 quencher to form SERSactive NPs by electrostatic and electronic interactions. We used QSY21 as the Raman
reporters because they do not have fluorescence background and they contain highly
delocalized pi-electrons that give strong SERS signals. To optimize the SERS NPs, we
used excess reporter molecules to saturate the surface coating. Using absorption
spectroscopy, we determined that approximately 1.2 x 104 QSY21 dye molecules were
adsorbed on each particle.

Figure 2.2. Schematic illustration of preparation of antibody-conjugated IO-Au SERS
NOVs targeting tumor cells.

We further examined the linearity, reproducibility and stability of the IO-AuSERS NPs with a Raman spectrometer. The signal intensity was linearly proportional to
the number of the NPs (Figure 2.3A). The NPs showed excellent stability after
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preparation, without signal changes within 3 days (Figure 2.3B). The signal decreased by
only 2.85 % after 14 days. The signals were repeatable from batch to batch, with an
intensity variation of less than 5% (Figure 2.3C). No signal reduction was observed after
repeated centrifugation and washings
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Figure 2.3. Determination of the linearity, reproducibility and stability of the IO-AuSERS NPs. (A) The SERS signal intensity at 1496 cm-1 as a function of the number of
QSY21-coated IO-Au NPs and (B) SERS spectra of QSY21-coated IO-Au NPs at
different times after preparation (C) SERS spectra of QSY21-coated IO-Au NPs made
from different batches of NPs. Signals in A were collected within 1s. Signals in B and C
were collected at 0.1s. excitation= 785 nm, Power= 50 mW, Beam size at focus = 200 m.
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The as-prepared NOVs had a hydrodynamic diameter (HD) and zeta potential ()
of 72 nm and 28 mV, respectively (Table 2.1). The NOVs were positively charged
because they were capped with a bilayer of the CTAB surfactant, which is similar to
other NPs such as gold nanorods that were prepared in the same growth solution181.
Coating the NOVs with the reporter molecules did not significantly change the HD and .
The QSY21-adsorbed NOVs were covalently linked with a mixture of HOOC-PEG-SH
and mPEG-SH (HOOC-PEG-SH/mPEG-SH = 2) to introduce functional groups for
ligand conjugation while stabilizing the SERS NPs. The PEG binding increased the
particle size by 23 nm and decreased the surface charge of the NPs to -14 mV.
Incorporation of neutral mPEG-SH molecules reduces the surface charge of the NPs and
thus minimizes nonspecific binding to cancer cells 182. Antibodies were linked to NPs
through amide bonds between the ligands and the heterofunctional PEG linkers via the
standard EDC/sulfo-NHS activated coupling reaction 182. The attachment of the
antibodies increased the HD of the NPs by 5 – 8 nm and  by 2 - 5 mV.

Table 2.1. Characterization of the preparation of conjugated IO-Au SERS NOVs by
dynamic light scattering.
Hydrodynamic Diameter Zeta Potential
(nm)
(mV)
IO-Au NOVs
72.0  2.2
28.5  0.5
QSY21/IO-Au NOVs
73.2  2.7
24.8  0.8
HOOC-PEG/mPEG/QSY21/IO-Au NOVs
96.1  1.5
-14.2  1.2
Anti-EpCAM/QSY21/IO-Au NOVs
104.2  3.1
-10.1  1.3
Anti-HER2/QSY21/IO-Au NOVs
103.5  3.5
-8.2  1.2
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To increase detection sensitivity, we made conjugated NPs to target two markers,
EpCAM and HER2. EpCAM is expressed on a vast number of epithelial tumor cells 183 .
HER2 is known to be overexpressed on nearly 30 % of breast cancer184. Both EpCAM 185
and HER2 receptors 186 are positive for SK-BR-3 cells.
To label the cancer cells, 10,000 SK-BR-3 cells were incubated with 5 pM antiEpCAM/QSY21/IO-Au NOVs and 5 pM anti-HER2/QSY21/IO-Au NOVs in PBS at
room temperature for 30 min with gentle shaking. Unconjugated NPs were used as the
control. The NP-treated cells were separated from free NPs by gentle centrifugation and
three washings, followed by fixation. (Figure 2.4A&B) show the dark field images of the
cancer cells incubated with the antibody-conjugated NOVs and unconjugated NOVs,
respectively. Specific cellular bindings of the conjugated NOVs were confirmed by the
presence of dense NPs on and/or in the cells, which in turn confirmed the successful
ligand conjugation to the NPs.

(A)

(B)

Figure 2.4. Antibody conjugation and cancer cell targeting of IO-Au NOVs. (A) Dark
field image of SK-BR-3 cells incubated with a cocktail of anti-EpCAM/IO-Au SERS
NOVs and anti-HER2/IO-Au SERS NOVs; and (B) Dark field image of SK-BR-3 cells
incubated with unconjugated IO-Au SERS NOVs. The data show specific binding of
antibody-conjugated IO-Au NOVs, but not the unconjugated ones, to the cancer cells.
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2.3.3. Design and construction of an integrated system for on-line cell capture
and detection.
Due to the scarcity of CTCs, a system that allows on-line isolation and detection
is desirable in order to minimize cell loss. Magnetic separation under flow conditions has
been shown to be an efficient way to capture NP-bound CTCs at appropriate flow rates
without capturing free NPs 104. This is because the magnetic force is proportional to the
number of bound NPs 29. The free NPs are more effectively removed by flow drag forces
than the cells which contain a number of NPs. We constructed a syringe-pumped flow
system and integrated it with permanents magnet to capture CTCs while separating
unbound NPs and blood cells (Figure 2.5A&B). The pump, which is precisely
programmable, works in a push/pull mode so that the sample can flow through the
capillary in both forward and backward directions. A strong and large magnet (magnet-1)
was used to isolate and capture tumor cells with high efficiency. It allows cell isolation at
high flow rates, enabling sample processing in a large volume within a short time. To
minimize cell loss, the system was coupled with a high throughput portable Raman
spectrometer so that purified and enriched cells can be directly detected on-line. During
the detection, the tumor cells need to be confined within the laser beam and immobilized
in the capillary so that they can be detected by the Raman spectrometer. Therefore, a
second magnet (magnet-2) was used to capture and concentrate the purified cells to a fine
region. The diameter of this magnet was designed to be the same as the diameter of the
Raman laser beam at focus. This ensures that all the tumor cells captured by the magnet
can be interrogated by the laser. Due to the small size, the magnetic field of the magnet-2
was much weaker than the magnet-1. This requires a much lower flow rate when the
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magnet-2 was used. We experimentally determined the optimal flow rate for the two
magnets by examining the effects of flow velocities on the cell/NP capture efficiency.
Figure 2.5C shows the capture efficiencies of pre-labeled SK-BR 3 cells and free IO-Au
NOVs at different flow velocities by the magnet-1. The data shows that the capture
efficiency of the cells were much higher than that of the free NPs at the same flow
velocity. The cell capture efficiency was 98 % while that of the NPs were 25 % at 1 cm/s.
When the flow velocity was increased to 6 cm/s, the cell capture efficiency decreased to
90 % while that of the NPs decreased to 2 %. Thus, cancer cells can be efficiently
captured at 6 cm/s without significant trapping of the free NPs. As for the small magnet2, it was designed to capture tumor cells that had been separated from the free NPs by the
magnet-1. Thus, the interference from free NPs is negligible. Figure 2.5D shows the
capture efficiencies of pre-labeled cancer cells by the magnet-2 at different flow
velocities. At 0.2 cm/s, the cell capture efficiency was 100%. The capture efficiency
decreased to 90 % at 1 cm/s and 80% at 2 cm/s, which were significantly lower than
those by the magnet-1 due to the much weaker magnetic field gradient of the magnet-2.
To ensure efficient capture efficiency, we used the flow velocity of 0.2 cm/s for the
capture and confinement of the separated cancer cells for SERS detection.
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Figure 2.5. Schematic and capture efficiency for cell capture and detection. (A)
Schematic illustration of the integrated system for on-line magnetic capture and SERS
detection of CTCs; (B) Top view of the magnets and the capillary in the flow system; (C)
Plot of the capture efficiencies of pre-labeled SK-BR-3 cells (black) and free IO-Au
NOVs (red) versus the flow velocity by the magnet 1; and (D) Plot of the capture
efficiency of pre-labeled SK-BR 3 cells versus the flow velocity by the magnet 2. The
major components of the system are a syringe pump, a quartz capillary, two cylindrical
NdFeB magnets and a portable Raman spectrometer. When the blood sample containing
NP-labeled tumor cells is introduced to the system, the syringe pushes the sample to flow
in the capillary. The tumor cells, but not free NPs and blood cells, are captured by the
magnet 1 in the absence of the magnet 2. After separation, the magnet 1 was removed,
and the cells are collected with PBS on-line and transferred to the magnet 2 where they
are captured and detected by the Raman spectrometer.
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2.3.4. Capture and detection of cancer cells.
Pre-labeled cancer cells in whole blood.
To validate the integrated system, we used SK-BR-3 cells labeled with IO-Au
NOVs in advance. We spiked the pre-labeled SK-BR-3 cells into whole blood with a
variety of concentrations (10-500 cells/mL) to determine the detection sensitivity. Each of
the samples was introduced to the flow system and pumped through the capillary at the
optimized flow velocity (6 cm/s, ~ 100 L/min) in the presence of magnet 1 to isolate the
tumor cells from the blood cells. After the isolation, the cells were enriched and
transferred back to the syringe by withdrawing a small amount of fresh PBS (100 uL)
from a reservoir at the end of the capillary while the magnet-1 was removed. Then, the
magnet-2 was attached and the cancer cells were pumped through the capillary again, but
at a much lower flow rate (0.2 cm/s, ~ 3.5 uL/min) so that they were captured by the
magnet-2. Real-time SERS measurement showed that the SERS signal intensity gradually
increased with time, indicating the capture of tumor cells by the magnet. The signal
intensity reached maximum when all the cells were confined and immobilized by the
micro-magnet. The total assay time for each sample on the system was 45-60 min.
Figure 2.6A shows the SERS spectra (averaged from three times experiments)
from different number of pre-labeled SK-BR-3 cells in 1 mL of whole blood. Each
spectrum was collected within only 1 s. The experiment was not performed on cell
concentration lower than 10 cells/mL due to the difficulty of spiking low number of cells
accurately and reproducibly. The SERS signals increased proportionally as the cell
number increased. A quantitative comparison was made using the peak at 1496 cm-1, the
strongest one in the whole spectral region (Figure 2.6B). The data shows excellent linear
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relationship between the signal intensity and the cell number, with correlation coefficient
(R2) of 99.8%. The blood (negative control) gave a background signal of 17 a.u. that was
13 times lower than the signal intensity when 10 cells were present (Figure 2.6C). Based
on the linear correlation between the signal intensity and the cell number, and the
background signals from the negative control, the LOD (the cell concentration required to
give a signal equal to the negative control plus three times the standard deviation of the
negative control) was calculated to be 0.2 cell/mL, less than 1 cell per mL of blood (99%
confidence). This indicates that cancer cells labeled with duplexed IO-Au SERS NOVs
can be captured under a flow condition via magnetic separation, followed by on-line
SERS detection with high sensitivity.
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Figure 2.6. Detection of pre-labeled SK-BR-3 cells spiked into whole blood. (A) SERS
spectra from different number of SK-BR-3 cells; (B) Plot of SERS signal intensity at
1496 cm-1 versus the number of SK-BR-3 cells; (C) Comparison of SERS signals from 10
pre-labeled SK-BR-3 cells in the blood and signals from the blood only (the negative
control). The calculated LOD was less than 1 cell/mL blood.

Spiked cancer cells in PBS.
The capability of the IO-Au NOVs and the integrated system for CTC capture and
detection was firstly tested with the use of cultured breast cancer cells in PBS. In these
studies, 1 mL of PBS containing varying number of fixed SK-BR-3 cells (10 – 500) was
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mixed with 5 pM (final concentration) anti-EpCAM/QSY21/IO-Au NOVs and 5 pM
(final concentration) anti-HER2/QSY21/IO-Au NOVs. After incubation (30 min), the
mixture was introduced to the flow system and CTCs were isolated, enriched and
detected using the integrated system. PBS containing the NPs at the same concentration,
but not cancer cells, was used as the negative control.
Figure 2.7A shows the SERS spectra from different number of cells in 1 mL of
PBS. Similar to pre-labeled cells, the signal intensity increased proportionally as the cell
number increased. However, under this condition, free NPs were present in the sample.
The SERS signal intensity at 1496 m-1 from free NPs (the negative control) is 51 a.u.,
distinct from the PBS background signals (19 a.u.) Figure 2.7B. This indicates slight
capture of the unbound NPs in the sample. However, the effect from the captured free
NPs for cell detection is not significant. As shown in Figure 2.7B, the peak intensity
increased to 267 a.u. with the presence of 10 cancer cells, which was more than 5 times
stronger than that from the negative control. Figure 2.7C&D shows the quantitative
relationship of SERS signal intensity at 1496 cm-1 with the cell number in the whole
range (10-500) and in the range of 10 to 100, respectively The data shows excellent
linear relationship between the signal intensity and the cell number (R2: 99.8%). Based
on the background signals from the negative control and the linear correlations shown in
Figure 2.7C, the LOD was calculated to be 1 cell per mL of PBS. This indicates that
tumor cells can be efficiently captured and detected on-line with high sensitivity using
IO-Au SERS NOVs.

44

(A)

(B)
300

12000

10
20
50
100
250
500

8000

250

SERS Intensity (a.u.)

SERS Intensity (a.u.)

10000

6000
4000
2000
0
300

600

900

10 cells + NPs in PBS
NPs in PBS
PBS

1200

1500

200
150
100
50
0
300

1800

(C)

1200

1500

1800

(D)
2500

12000

2000

-1

10000

SERS intensity at 1496 cm (a.u.)

-1

SERS intensity at 1496 cm (a.u.)

900

Raman Shift (cm )

Raman Shift (cm )

8000
6000
4000
2000
0

600

-1

-1

0

100

200

300

400

500

Number of Cancer Cells

1500
1000
500
0

Negative control

0

25

50

75

100

Number of Cancer Cells

Figure 2.7. Detection of SK-BR-3 cells spiked into PBS. (A) SERS spectra from
different number of SK-BR-3 cells; (B) Comparison of SERS signals from NPs in PBS,
10 SK-BR-3 cells plus NPs in PBS, and signals from PBS only; (C) Plot of SERS signal
intensity at 1496 cm-1 versus the number of SK-BR-3 cells from 10-500 cells; and (D)
Enlarged plot of SERS signal intensity at 1496 cm-1 versus the number of SK-BR-3 cells
from 10-100 cells. SERS signal intensity at 1496 cm-1 from the NPs in PBS (the negative
control) is shown for comparison. The calculated LOD was 1 cell/mL PBS.
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Spiked cancer cells in whole blood.
To mimic CTCs, we spiked cultured SK-BR-3 cells into human whole blood. To
determine the detection sensitivity, 10, 20, 50, 100, 250 and 500 cancer cells were spiked
into 1 mL whole blood. Each sample was incubated with 5 pM anti-EpCAM/QSY21/IOAu NOVs and 5 pM anti-HER2/QSY21/IO-Au NOVs for 30 min with gentle shaking to
allow the binding of conjugated IO-Au SERS NOVs to the cancer cells. After reaction,
the sample was introduced to the flow system and CTCs were isolated, enriched and
detected using the procedures described above. To examine the detection specificity, 1
mL whole blood without cancer cells was incubated with the same concentration of antiEpCAM/QSY21/IO-Au NOVs and anti-HER2/QSY21/IO-Au NOVs for 30 min,
followed by magnetic separation and SERS detection using the integrated system. The
free NPs in PBS were used as another control to investigate the nonspecific binding of
the conjugated NPs to blood cells. A third control was the blood in the absence of the
conjugated NPs and cancer cells.
Figure 2.8A shows the SERS spectra from different number of cells. Similar to
the cancer cells spiked into PBS, the signal intensity increased proportionally as the cell
number increased. A comparison of the averaged SERS signals from the three negative
controls and the sample with low number of cancer cells (10 cells) was shown in Figure
2.8B. At 1469 cm-1, the signal intensity from blood only, free NPs in PBS, free NPs in
blood, and 10 cells plus free NPs in the blood was 17, 52, 134 and 312 a.u., respectively.
The weak signals from free NPs in PBS is due to the modest capture of the NPs by the
permanent magnets, as described earlier. When the blood was incubated with the
conjugated NPs, the signal intensity increased by 1.5-fold compared to that from free NPs
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in PBS. When the blood was spiked with 10 cells and incubated with the conjugated NPs,
the signal intensity increased by 5-fold. These results indicate that the nonspecific
binding of the conjugated NPs to blood cells is remarkably low, considering the fact that
1 mL of whole blood contains 10 million white blood cells and 5 billion red blood cells
169

. The SERS signal intensity at 1496 cm-1 shows an excellent linear correlation with the

cell number (R2: 99.8%) (Figure 2.8C). The negative control (free NPs in the blood) gave
a background signal that was significantly lower than those from tumor cells (Figure
2.8D). Based on the background signals from the free NPs and the linear correlation
between the peak intensity and cell number, the LOD was calculated to be 1-2 cells per
mL of blood.
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Figure 2.8. Detection of SK-BR-3 cells spiked into whole blood. (A) SERS spectra from
different number of SK-BR-3 cells; (B) Comparison of the SERS signals from NPs in
PBS, NPs in blood, 10 SK-BR-3 cells plus NPs in blood and signals from blood only; (C)
Plot of SERS signal intensity at 1496 cm-1 versus the number of SK-BR-3 cells from 10500 cells; and (D) Enlarged plot of SERS signal intensity at 1496 cm-1 versus the number
of SK-BR-3 cells from 10-100 cells. SERS signal intensity at 1496 cm-1 from NPs in
blood (the negative control) is shown for comparison. The calculated LOD was 1-2
cells/mL blood.
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This is 25 times more sensitive than previous assay in which anti-EpCAM
conjugated magnetic beads were used for magnetic separation and anti-HER2 conjugated
SERS Au NPs were used for optical detection 92. The improved detection sensitivity with
our method is mainly due to the use of IO-Au hybrid NPs that not only capture the cancer
cells but also detect them. Thus, cancer cells with either of HER2 and EpCAM markers
or both can be simultaneously captured and detected. In addition, the use of nanoscale
magnetic NPs rather than magnetic bead enhances cell binding affinity 28. Furthermore,
the integration of magnetic separation, high throughput Raman detection and capillary
flow system ensures that all cells captured by the magnet are detected.
2.4. CONCLUSION
Using CTC-mimic breast cancer cells as a model, the application of magneticoptical hybrid NPs for dual capture/detection of CTCs in whole blood was demonstrated
for the first time. We developed compact IO-Au core-shell NPs in oval shapes, with
combined superparamagnetic properties and SERS activities. Our studies showed that
novel IO-Au SERS NOVs combined with duplex targeting and an on-line capture and
detection system allow high sensitivity detection of cancer cells in whole blood (LOD: 12 cells/mL blood), without tedious sample preparations and complex techniques. Our
method provides a huge step forward in developing a simple, rapid, quantitative and
ultrasensitive technique for rare cell detection, which will make an important impact in
the field of cancer medicine.
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Chapter 3. Gold Nanorods Carrying Paclitaxel for Photothermal-Chemotherapy of
Cancer

Nanotechnology-based photothermal therapy has emerged as a promising
treatment for cancer during the last decade. However, heterogeneous laser heating and
limited light penetration can lead to incomplete tumor cell eradication. Here, we
developed a method to overcome these limitations by combining chemotherapy with
photothermal therapy using paclitaxel-loaded gold nanorods. Paclitaxel was loaded to
gold nanorods with high density (2.0 x 104 paclitaxel per gold nanorod) via nonspecific
adsorption, followed by stabilization with poly(ethylene)signals glycol linked with 11mercaptoundecanoic acid. Paclitaxel was entrapped in the hydrophobic pocket of the
polymeric monolayer on the surface of gold nanorods, which allows direct cellular
delivery of the hydrophobic drugs via the lipophilic plasma membrane. Highly efficient
drug release was demonstrated in a cell membrane mimicking two-phase solution.
Combined photothermal therapy and chemotherapy with the paclitaxel-loaded gold
nanorods was shown to be highly effective in killing head and neck cancer cells and lung
cancer cells, superior to photothermal therapy or chemotherapy alone due to a synergistic
effect. The paclitaxel-gold nanorod enabled photothermal-chemotherapy has the potential
of preventing tumor reoccurrence and metastasis and may have important impact on the
treatment of head and neck cancer and other malignancies in the clinic.
3.1. INTRODUCTION
During the past decade, nanotechnology-enabled photothermal therapy (PTT) has
emerged as a potential anticancer treatment and generated a great deal of interest in
nanomedicine. This technique is based on the use of nanostructures, including silica/gold
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nanoshell 113-115,187,188, gold nanorods (Au NRs)119,120,189, gold nanocages and hollow gold
nanospheres 122,124,190-192 and carbon nanotubes that absorb strongly within the tissuetransparent near infrared (NIR) region. Treatment with nanoparticles (NPs) and
subsequent irradiation with a NIR laser creates heat sufficient to induce tumor ablation.
In comparison to other approaches, nanotechnology-based PTT has several advantages. It
is a non-invasive and localized treatment. The anticancer effect is instant and the degree
of effect can be controlled by the applied dosage of the external light. The therapeutic
effect does not require intracellular uptake of the nanodrugs. However, PTT faces
significant barriers. Complete eradication of cancer cells under laser irradiation is
difficult because of the uneven heat distribution within the tumor caused by the
heterogeneous distribution of NPs and the Gaussian distribution of the energy of the laser
beam. In addition, the applied light intensity gradually reduces as it travels through tissue,
leading to inefficient killing of tumor cells in deeper tissues. Thus, new strategies are
needed to overcome these limitations.
One of the most promising approaches is to combine PTT with chemotherapy.
Combined PTT and chemotherapy has been shown to be more effective than the two
treatments alone due to additive or synergistic effects 125,193-201. For example, Chan and
co-workers reported that the combination therapy with Au NR-enabled hyperthermia and
physically mixed cisplatin led to 84% more cell killing than hyperthermia alone and 78%
more than cisplatin alone 202. Combination therapy is also capable of reducing
chemotherapy-associated toxicity by means of lowering the effective drug dosage.
However, current methods depend mainly on a light triggered mechanism to release the
chemotherapeutic drugs from the nanocarriers 181,182,203-208. Such treatments can be finely
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controlled through manipulation of the externally applied laser light. This approach
prevents systemic toxicity due to off target release of chemotherapeutic drugs. However,
tumor cells in deep tissues may not be destroyed due to limited laser penetration.
Here, we report a new system for combined PTT and chemotherapy using NIRabsorbing Au NRs carrying chemotherapeutic paclitaxel (PTX). We made highly
integrated PTX-Au NR complex in which PTX was entrapped with high density in the
hydrophobic pocket of alkanethiol-linked poly(ethylene) glycol (PEG) monolayer on the
surface of Au NRs. The nanocomplex allows drug release and cellular delivery of the
hydrophobic drug through partitioning of the drug within the lipophilic plasma
membrane, which is light independent. The chemotherapeutic drug can therefore
eradicate malignant cells outside the laser path, overcoming the limitation associated with
PTT. We demonstrated that the PTX-Au NR complexes did not exhibit significant drug
release in physiological environments, but efficiently released their payload in a cell
membrane mimicking two-phase solution. The combined PTT and chemotherapy with
the PTX-Au NR complex showed excellent efficacy for the treatment of cancer cells of
different origin, superior to PTT or chemotherapy alone. As the nanocomplex uses a
hydrophilic PEG protective layer that minimizes non-specific uptake by the reticuloendothelial system (RES) 209, passive tumor targeting would be achieved for in vivo and
clinic applications through the enhanced permeability and retention (EPR) effect of solid
tumors 210. The novel single-particle drug delivery system may have important impact on
preventing cancer reoccurrence and metastasis.
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3.2. MATERIALS AND METHODS
Materials.
All chemicals were purchased from Sigma-Aldrich unless specified. Amineterminated poly (ethylene) glycol (PEG-NH2, MW 5000) was purchased from Laysan Bio
(Arab, AL). PTX was purchased from LC Laboratory (Woburn, MA).
Synthesis and characterization of Au NRs.
Au NRs with an aspect ratio of 3.7 were synthesized according to the seedmediated growth method 211. Briefly, 2 to 5 nm Au NPs were synthesized as a seed
solution by the reduction of chloroauric acid (HAuCl4) (2 mL, 0.25 mM) with ice-cold
sodium borohydride (NaBH4) (120 μL, 10 mM) in the presence of 0.1 M CTAB. A
growth solution (100 mL) containing 0.5 mM HAuCl4, 0.1 M CTAB, and 80 uM AgNO3
was prepared, followed by the addition of ascorbic acid (1.40 mL, 80 mM). A volume of
140 μL of the seed solution was injected into the growth solution, followed by 10 s of
mixing and 2 h of standing to allow completion of NR growth. The resulting Au NRs
were purified via three rounds of centrifugation and wash (12,000 rpm, 20 min,
Eppendorf 5804 R) and were stored in ultra-pure water at RT. Optical absorption
spectrum was measured using a UV-VIS-NIR absorption spectrometer (Agilent, Santa
Clara, CA). The NRs were quantified using the extinction coefficient determined by
Orendorff et al 212. The morphology and size of the NRs were determined using
transmission electron microscopy (TEM) (Joel JEM1200 EX II, Tokyo, Japan).
Hydrodynamic size and zeta potential were measured by dynamic light scattering (DLS)
(Brookhaven 90 plus particle size analyzer, Holtsville, NY).
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Preparation and characterization of 11-mercaptoundecanoic acid - linked
poly(ethylene) glycol (MUA-PEG).
MUA (final concentration: 1 mM) was dissolved in 4 mL of anhydrous
dichloromethane (DCM), followed by the addition of PEG-NH2 (10 mg) and 4(dimethylamino) pyridine (DMAP) (0.1 mg). Then, N,N’-dicyclohexylcarbodiimide
(DCC) (0.8 mg) was added and the mixture was stirred overnight in the dark. After
solvent evaporation, the residue was reconstituted in ultrapure water and was purified
with a 0.2 um filter to separate excess organic precipitates. Then, dithiothreitol (DTT)
(final concentration: 1 mM) was added and the solution was stirred for 30 min in the
dark. The final solution was purified by three times of centrifugation (8,500 rpm, 20 min)
using a centrifugal filter (MWCO 3000, Millipore). The product was characterized by
absorption spectroscopy and nuclear magnetic resonance (NMR) spectroscopy. To collect
the NMR spectrum, the sample was lyophilized in the dark overnight, followed by
reconstitution with deuterated chloroform (CDCl3). 1H spectrum was recorded on a
Varian 500 MHz NMR spectrometer. 1H spectra of MUA and NH2−PEG were collected
for comparison. 1H NMR (CDCl3) for MUA: δ 1.29 (m, 12H), 1.34 (t, 1H, J = 7.6 Hz),
1.62 (m, 4H), 2.36 (t, 2H, J = 7.6 Hz), 2.53 (q, 2H, J = 7.6 Hz), 11.25 (br s, 1H); 1H
NMR (CDCl3) for NH2−PEG: δ 1.80 (br s, 2H), 2.92 (t, 2H, J = 5.2 Hz), 3.38 (s, 3H),
3.52 (m, 2H), 3.54−3.83 (m, 418 H); 1H NMR (CDCl3) for MUAPEG: δ 1.28 (m, 12H),
1.34 (t, 1H, J = 7.3 Hz), 1.62 (m, 4H), 1.83 (m, 14H), 2.17 (t, 2H, J = 7.3 Hz), 2.41 (t, 1H,
J = 7.3 Hz), 2.53 (q, 2H, J = 7.6 Hz), 2.67 (t, 1H, J = 7.3 Hz), 2.85 (t, 2H, J = 7.3 Hz),
3.38 (s, 3H), 3.53 (m, 2H), 3.58−4.20 (m, 423H), 5.35 (br s, 1H), 6.24 (s, 1H).
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Preparation and characterization of PTX-loaded, MUA-PEG-stabilized Au NRs
(MUA-PEG/PTX/Au NRs).
PTX dissolved in dimethyl sulfoxide (DMSO) (6 uL, 5 mM) was added to Au
NRs (1 mL, 0.5 nM) and the mixture was stirred for 15 min (Scheme 1). Then, MUAPEG (30 uL, 1 mM) was added and the solution was stirred for 40 min. The MUAPEG/PTX/Au NRs were purified by three rounds of centrifugation (12,000 rpm, 20 min)
and the residue was reconstituted with ultrapure water. The nanocomplexes were
characterized by absorption spectroscopy and DLS. To determine PTX content, the
nanocomplexes (100 uL, 0.5 nM) were mixed with DCM (500 uL) with vigorous stirring.
After 4 h, the DCM solution was collected and the solvent was removed by evaporation.
The residue was reconstituted with methanol and analyzed on an Acquity UPLC system
coupled with mass spectrometry (Waters, Milford, MA) with a reverse-phase C18 column
(pore size: 1.7 um). The number of MUA-PEG was determined using the N-succinimidyl
3-(2-pyridyldithio) propionate (SPDP) method 182. In this method, we assumed thiolated
PEG with the same molecular weight have similar binding affinity to Au NRs. Thus, the
number of MUA-PEG on Au NRs was determined using HS-PEG-NH2. The number of
HS-PEG-NH2 on Au NR was determined by the reaction of SPDP with the primary
amine to generate pyridine- 2-thione that can be quantified by UV−vis absorption 208.
The stability of MUA-PEG/PTX/Au NRs in PBS, medium and serum.
MUA-PEG/PTX/Au NRs were resuspended in PBS, cell culture medium or serum
after preparation to make 1 mL of 0.5 nM (concentration of Au NR) solution. The
solution was constantly shaken (600 rpm) on an orbital shaker. At specified times from
30 to 360 min, 200 uL of the solution was withdrawn and centrifuged to separate PTX

55

released from the PTX-Au NR complex. PTX in the supernatant was extracted with an
equal volume of DCM, filtered with a 0.22 um syringe filter and analyzed by UPLC.
PTX release in a two-phase solution.
MUA-PEG/PTX/Au NRs (200 uL, 0.5 nM) were added gently on top of 200 uL
of DCM solution. At specified times from 10 to 360 min, the organic solution was
collected and centrifuged to separate PTX released from the PTX-Au NR complex. After
solvent evaporation, the residue was reconstituted with methanol, filtered with 0.22 um
syringe filter and analyzed by UPLC.
Cellular uptake of PTX from MUA-PEG/PTX/Au NRs.
A549 (lung cancer) cells were seeded at a density of 8 x 103 cells per well into 96well plates in triplicate. After 24 h, the medium was replaced with fresh medium
containing 0.1 nM MUA-PEG/PTX/Au NRs. At a specified time from 30 to 360 min, the
cell culture medium was collected. PTX in the medium were extracted with DCM and
analyzed with UPLC. PTX released was expressed as the percentage of PTX inside cells
compared to the total amount of PTX from the MUA-PEG/PTX/Au NRs added to the
medium.
Cell culture and cell viability assay.
KB-3-1 (head and neck cancer) and A549 cells were cultured in RPMI 1640
medium supplemented with 10% (v/v) FBS and penicillin−streptomycin solution (100
U/mL penicillin, 100 U/mL streptomycin) at 37 °C under 5% CO2. The cells were seeded
at a density of 8 × 103 cells per well into 96-well plates in triplicate. After 24 h, PTX
(PBS or DMSO as the solvent) or equivalent concentration of MUA-PEG/PTX/Au NRs
were added at various final concentrations (11, 22, 45, 90, 180 and 360 nM) and were
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continuously incubated for 24, 48 or 72 h. Cell viability was determined using the XTT
((2,3-bis[2-Methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxyanilide inner salt)
toxicology assay. The cell viability was expressed as the percentage of live cells over that
of the untreated control. The data are presented as the mean  standard deviation of
triplicate measurements. IC50 values were determined by fitting the dose-effect curves
according to a four-parameter logistic model with OriginPro 8 software (Origin Lab
Corp, Northampton, MA).
To examine the potency of combination treatment, the cells were exposed to the
following treatments: (1) PTX (DMSO as solvent), (2) MUA-PEG/PTX/Au NRs, (3)
MUA-PEG/Au NRs plus laser irradiation, (4) MUA-PEG/PTX/Au NRs plus laser
irradiation and (5) control without any treatment. The laser treatment, 10 min irradiation
with NIR light (=808 nm. Beam size, 5 mm. Power intensity 0.55 W/cm2)(Diode laser,
Power Technologies, Little Rock, AR) was conducted immediately following the addition
of drug formulations. Cells were incubated with the drug formulations for 1 h after which
they were washed with PBS and incubated in drug-free medium for 48 h. Cell viability
was determined using the XTT assay. The concentration of Au NRs was 0.1, 0.3 and 0.5
nM. Free drug was added at an equivalent concentration of PTX.
Statistical analysis.
Data were expressed as means of three replicated experiments. The statistical
significance of the cell viabilities under different treatments and different concentrations
were compared using the analysis of variance (ANOVA). A p-value < 0.05 of ANOVA
was considered statistically significant in all cases. Multiple comparison procedures were
used after obtaining a significant ANOVA result. Hence, a post hoc Scheffe method was
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applied to determine which means differed. The mean difference between treatments or
concentrations was considered to be significant if the absolute value was greater than the
minimum significant difference (MSD) which was derived from Scheffe method.
3.3. RESULTS AND DISCUSSION
3.3.1. Synthesis and characterization of Au NRs.
In order to maximize photothermal effect in the NIR region, we prepared Au NRs
with aspect ratio of 3.7 which were averagely 55 nm in length and 15 nm in width (Figure
3.1A). These Au NRs had a longitudinal localized surface plasmon resonance (LSPR)
peak at 780 nm (Figure 3.1B) which overlapped well with the laser wavelength (785 nm).
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Figure 3.1. (A) TEM micrograph and (B) absorption spectrum of Au NRs. Au NRs had
an aspect ratio of 3.7, with the surface plasmon resonance peaks at 520 nm and 780 nm.
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The surface of the Au NRs have been shown to be capped with the CTAB surfactant in a
bilayer structure along the long-axis direction 213 (Figure 3.2).

Figure 3.2. Schematic illustration of the synthesis of MUA-PEG/PTX/Au NRs. MUAPEG/PTX/Au NRs were formed by nonspecific adsorption of PTX onto Au NRs
followed by stabilization with MUA-PEG.

In this conformation, one CTAB binds to the Au surface with its ammonium head and
interacts with another CTAB with its long hydrocarbon chain. The ammonium headgroup
of the second CTAB is exposed to the solution, making the NRs water soluble and
positively charged. The two layers of CTAB provide a hydrophobic pocket that allows
direct adsorption of hydrophobic drugs without a need for additional modifications of the
drug or the Au NR.
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3.3.2. Preparation and characterization of 11-mercaptoundecanoic acid linked poly(ethylene) glycol (MUA-PEG).
MUA-PEG was synthesized by the standard DCC-activated coupling reaction in
organic phase between PEG-NH2 and bifunctional MUA. The two molecules were linked
by an amide bond leaving the thiol group for binding to Au NRs. We used excessive
MUA in order to convert NH2-PEG to MUA-PEG with high efficiency. The extra MUA
after reaction was separated by centrifugal filtration. The formation of MUA-PEG was
confirmed by the 1H spectra (Figure 3.3). MUA gives the characteristic S-H triplet at
δ=1.34 ppm 209. The strong peak at 1.29 ppm was from the 6 methylene in the alkyl
chain. The COOH of MUA gives a weak and broad peak at 11.25 ppm. The NH2-PEG
shows a weak peak at δ = 1.80 ppm from the primary amine 210. The multiple protons
from −CH2CH2O− unit give strong peaks from 3.54 to 3.83 ppm. The chemical shift of
protons in the −OCH3 group was at 3.38 ppm. The 1H NMR spectrum of MUA-PEG
shows a combination of that from MUA and NH2-PEG, but with the disappearance of the
−COOH at 11.25 ppm and the appearance of a weak new peak at 5.35 ppm which was
assigned to the secondary amine 214.
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Figure 3.3. 1H NMR spectra of MUA (top), NH2-PEG (middle), and MUA-PEG
(bottom). The 1H NMR spectrum of MUA-PEG shows a combination of that from MUA
and NH2-PEG, but with the disappearance of the −COOH at 11.25 ppm and appearance
of −NH− at 5.35 pm, suggesting the formation of amide bond between MUA and NH2PEG. Inset shows the enlarged 1H spectrum of the triplet peak from −SH in MUA.
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These results demonstrated that amide bond was formed between MUA and NH2PEG. The lack of a COOH peak indicated that excessive MUA had been successfully
separated from the product by centrifugal filtration. Due to the overlap of the signals
from the primary amine in NH2-PEG and those from methylene in MUA, it is difficult to
determine whether primary amines were present. However, we determined that the ratio
of peak area from a and d (−SH and −(CH2)6) to a′ (−OCH3) is about 4.2, similar to the
ratio of these protons in MUA-PEG. This indicates that NH2-PEG was not present in the
product. This is not surprising as we added 2 times more MUA to react with NH2-PEG in
order to completely convert NH2-PEG to MUA-PEG. The peak at 1.83 ppm was from
water that was not completely removed during lyophilization. This was confirmed by the
fact that the peak intensity at 1.83 ppm increased when a small amount of water was
added to MUA-PEG dissolved in CDCl3 (Figure 3.4).

Figure 3.4. H NMR spectrum of MUA-PEG in CDCl3 with the presence of a small
amount of water. The water shows a strong peak at δ=1.83 ppm.
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No other chemicals were found in the product, indicating the high purity of MUA-PEG.
The MUA-PEG was quantified by the absorption spectrum (Figure 3.5). As shown in
Figure 3.5, MUA-PEG shows an absorption peak at 236 nm, similar to the absorption
peak from methoxy-PEG-SH (mPEG-SH, MW 5000, Laysan Bio).
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Figure 3.5. Absorption spectrum of MUA-PEG and mPEG-SH. The concentration of
mPEG-SH is 1 mM.

We assume mPEG-SH and MUA-PEG have the same absorption coefficient due
to their structural similarity. Using the absorption coefficient determined from mPEG-SH
(ε = 1.6 × 103 M−1 cm−1), we determined that the yield of MUA-PEG is 71%. Most
likely, sample loss occurred during the multiple periods of centrifugation and washing,
which were applied for purification.
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3.3.3. Preparation and characterization of MUA-PEG/PTX/Au NRs.
Hydrophobic drugs constitute a large part of commercially available drugs.
However, it remains a challenge to load hydrophobic drugs to aqueous NIR-absorbing
NPs for PTT-chemotherapy. Previously, You et al. combined PTX with gold nanocages
within a poly(lactide-co-glycolide) (PLGA) microspheres for light-triggered drug release
and PTT-chemotherapy of cancer 215. In 2009, Kim et al. demonstrated that hydrophobic
molecules could be trapped in the Au NP monolayer formed by 11-mercaptoundecanoic
acid (MUA)-linked tetra (ethylene glycol) (TEG) units (MUA-TEG) through a solvent
evaporation method 216. Such formulation allows drug delivery through hydrophobic
interactions of the drug in the nanocomplex with the apolar sites of lipid membrane. For
in vivo and clinic applications, much thicker PEG layer is required to sterically hinder
plasma protein adsorption, extend blood circulation time and correspondingly increase
specific tumor accumulation via the EPR effect. Thus, we used MUA-PEG (MW 5000)
to entrap PTX on the surface of Au NR.
We made MUA-PEG/PTX/Au NRs via a simple two-step procedure (see Figure
3.2). First, PTX was adsorbed onto Au NRs via hydrophobic interaction of the molecule
with the CTAB capping materials. Then, amphiphilic MUA-PEG was added to replace
CTAB while stabilizing the PTX-adsorbed Au NRs. This process was finished within one
hour and did not require pre-modifications of the drug or the carrier. Figure 3.6 shows the
absorption spectra of PTX, Au NRs modified with MUA-PEG only, and Au NRs
modified with PTX and MUA-PEG.
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Figure 3.6. Characterization of PTX loading by absorption spectroscopy. The MUAPEG/PTX/Au NRs showed the absorption peaks of both PTX and Au NRs, indicating
successful formation of PTX-Au NR complexes.

The absorption spectrum of MUA-PEG/Au NRs is similar to that of CTABcapped Au NRs (see Figure 3.1). Although MUA-PEG absorbs at 236 nm (Figure 3.5),
MUA-PEG/Au NRs do not show obvious absorption from the surface molecules. This is
because the absorption coefficient of MUA-PEG is low, ∼106 times lower than that of Au
NRs. Compared to MUA-PEG modified Au NRs, the MUA-PEG/PTX/Au NRs gave an
additional absorption peak at 232 nm from PTX, indicating the success of drug loading.
Using UPLC analysis, we found that as much as 2.0 × 104 PTX were loaded per Au NR.
Using the SPDP method 208, we determined that 1.1 × 104 MUA-PEG were loaded per Au
NR. Based on the surface density and the molecular weight of PTX and MUA-PEG as
well as the size of Au NR and the density of Au, we determined that the content of PTX
and MUA-PEG in the MUA-PEG/PTX/Au NR was 9.3% (wt %) and 38.7% (wt %),
respectively.

65

DLS measurements (Table 3.1) showed that CTAB-capped Au NRs had the
hydrodynamic size of 49 nm and zeta potential of +37 mV. When the NRs were modified
with MUA-PEG alone, the average hydrodynamic size of the NRs increased to 81 nm
and the zeta potential decreased to −6 mV. The MUA-PEG/PTX/Au NRs were about 7
nm larger than their MUA-PEG/ Au NR in size, but similar in surface charges. These
results suggest that MUA-PEG replaced CTAB to stabilize the adsorbed PTX rather than
displacing the drug from the metal surface.

Table 3.1. Characterization of drug loading by dynamic light scattering.
Hydrodynamic Size
(nm)

Zeta Potential
(mV)

CTAB/Au NRs

48.9 ± 1.3

+37 ± 1.8

MUA-PEG/Au NRs

81.3 ± 2.1

-5.8 ± 0.3

MUA-PEG/PTX/Au NRs

87.9 ± 1.8

-7.4 ± 0.6

This enabled the formation of highly integrated PTX-Au NR complexes in which PTX is
entrapped in the hydrophobic interior of the MUA-PEG monolayer. The hydrophilic PEG
exterior makes the nanocomplex physiologically stable.
3.3.4. Stability of MUA-PEG/PTX/Au NRs in PBS, medium and serum.
One of the key issues for successful combination treatment is controlling the drug
release at tumor sites. The nanocomplex should not exhibit significant drug release in the
off-target blood system. We therefore examined whether the nanocomplexes were stable
in PBS, cell culture medium and 100% serum under mobile conditions. To mimic blood
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circulation, the nanocomplxes in the above solutions were continuously shaken on an
orbit shaker. Aliquot of the solution was extracted at different time, processed with
solvent extraction and analyzed with UPLC to determine the content of released PTX.
We found that only 1% of PTX was released after 1 h in all the solutions (Figure 3.6).
After 6 h, less than 10% of PTX was released in all cases. These results demonstrate that
the nanocomplexes are stable in PBS, medium or serum, indicating their great stability in
blood circulation.

10
PBS
Medium
Serum

PTX Release (%)

8
6
4
2
0

0

50

100

150

200

250

300

350

400

Time (min)
3.7. Stability of MUA-PEG/PTX/Au NRs in PBS, cell culture medium and serum. The
solutions were kept constant by shaking on an orbit shaker and the amount of released
PTX at different times was measured by UPLC.
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3.3.5. PTX release from MUA-PEG/PTX/Au NRs in a two-phase solution and
cellular environment.
Hydrophobic drugs preferentially localize to apolar sites, such as lipid
membranes, with a high partition coefficient

217

. This property provides a great

opportunity for intracellular delivery of hydrophobic drugs without the use of external
triggers

218,219

. To demonstrate PTX release from the MUA-PEG/PTX/Au NRs in vitro,

we used a water/DCM two-phase solution to mimic the lipid membrane. In this study,
MUA-PEG/PTX/Au NRs were exposed to an equal volume of DCM and the amount of
PTX in the organic phase was quantified as a function of time by UPLC. The
nanocomplex exhibited a biphasic release profile with the rapid release process occurring
within 2 h (Figure 3.7A).
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Figure 3.8. PTX release from nanocomplex. (A) Release profile of PTX from MUAPEG/PTX/Au NRs in a two-phase solution. 200 uL of 0.5 nM MUA-PEG-PTX/Au NRs
in water was exposed to equal amount of DCM. PTX in the DCM layer at different time
was quantified with UPLC. (B) Release profile of PTX from MUA-PEG/PTX/Au NRs
under cellular environment. A549 cells (in 96-well cell culture plate) were exposed to
100 μL of cell culture medium containing 0.1 nM MUA-PEG-PTX/Au NRs. PTX in cells
was quantified by determination of PTX in the supernatant of medium with UPLC.
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At this time, 50% PTX was released from the complex. At 6 h, the amount of released
PTX increased to 76%, suggesting highly efficient drug release of the nanocomplex. The
drug release process occurred at the water-DCM interface, based on the fact that only a
trace amount of Au NRs (< 5%) was found in the organic phase. A potential concern with
the two phase model is the dissociation of MUA-PEG from the surface of Au NR due to
the solvent extraction, which could accelerate the release of PTX. To examine whether
MUA-PEG was displaced from the surface of Au NR during extraction, we measured the
1

H spectrum of the organic phase at 3 h after mixing 200 uL of 0.5 nM MUA-PEG/Au

NRs and 200 uL of DCM. Figure 3.8 shows that no chemicals were found in the DCM
phase. This indicates that MUA-PEG was not displaced during the two-phase studies.

Figure 3.9. 1H NMR spectra of the DCM phase at 3 h after mixing 200 uL of 0.5 nM
MUA-PEG/Au NRs in water with 200 uL of DCM. No chemicals were found in the
DCM phase, indicating the lack of MUA-PEG in the DCM during the two phase
experiment.
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We have demonstrated efficient PTX release using a membrane-mimic
water/DCM system. However, the two-phase system does not represent a true model of
cell system. Thus, we further examined the drug release profile when the nanocomplexes
were exposed to cancer cells. In this study, we incubated A549 cells with cell culture
medium containing MUA-PEG/PTX/Au NRs. After a specified time from 10 to 360 min,
we determined the amount of PTX inside cancer cells by measuring PTX remaining in
the supernatant medium at different time of incubation. Figure 3.7B shows the percentage
of PTX released (i.e. percentage of PTX inside cells) when MUA-PEG/PTX/Au NRs (0.1
nM, 100 uL) were incubated with A549 cells (in 96-well plate). The nanocomplex
exhibited a biphasic release profile with the rapid release process occurring within the
first hour. Then, PTX release was slowly increased, with 64% of PTX released at 6 h.
PTX release in the presence of cells is significantly accelerated compared to that in the
absence of cells (Figure 3.1). This could be due to the effects from increased temperature
(room temperature to 37oC) and the presence of cells. To examine the temperature
effects, we incubated cell culture medium containing MUA-PEG/PTX/Au NRs at 37oC
for 6 h and then measured free PTX in the medium. We found that 13% PTX was
released, which was slightly higher than that at room temperature (9 %). Thus, the high
efficiency of drug release in the presence of cells was mainly due to the effects from the
lipid membrane of cells.
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3.3.6. Cytotoxicity of MUA-PEG/PTX/Au NRs.
Chemotherapy is one of the major components in the combination treatment.
Therefore, we firstly determined the anticancer activity of MUA-PEG/PTX/Au NRs as a
chemotherapeutic agent using XTT assay. Two cell lines with different origins: KB-3-1
(head and neck cancer) and A549 (lung cancer) were used to test our reagents. Figure 3.8
shows the percentage viabilities of KB-3-1 and A549 cells (relative to the control) after
24, 48 and 72 h incubation with free PTX delivered in DMSO and MUA-PEG/PTX/Au
NRs at varying PTX concentrations.
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Figure 3.10. Cytotoxicity of free PTX and MHDA-PEG/PTX/Au NRs in KB-3-1 and
A549 cells after 24, 48 and 72 h incubation. The results are mean values  SD of
triplicate experiments. The MHDA-PEG/PTX/Au NRs showed comparable anticancer
activities to the free PTX in both cell lines.

73

Both free PTX and PTX-loaded Au NRs showed time- and dose-dependent anticancer
activities. The nanocomplex showed comparable cytotoxicity to the free drug against
both cell lines. Table 3.2 summarizes the IC50 of free PTX and MUA-PEG/PTX/Au NRs
under different conditions.

Table 3.2. IC50 of free PTX and MUA-PEG/PTX/Au NRs after 24, 48 and 72 h
incubation in KB-3-1 and A549 cells.
IC50 (nM PTX)
Cell line Incubation time (h)
PTX
MUA-PEG/PTX/Au
NRs
24
80 ± 2.0
96 ± 2.4
KB-3-1
48
45 ± 0.8
50 ± 1.1
72
22 ± 0.1
24 ± 0.4
24
83 ± 2.5
77 ± 1.6
A549
48
53 ± 1.2
44 ± 1.7
72
31 ± 0.5
23 ± 0.3

The IC50 of MUA-PEG/PTX/Au NRs ranged from 20 to 100 nM depending on the
incubation time and the cell line. Increasing the drug exposure time lead to decreased
IC50 and thus better cell killing effect of the drug. The MUA-PEG/PTX/Au NRs showed
slightly higher IC50 than free PTX in KB-3-1 cells but vice versa in A549 cells. The
delayed drug release from the nanocomplex generally lead to lower cell killing potency
of the nanocomplex than the free drug. However, the sustained drug release may protect
PTX from epimerization and hydrolysis in the cellular environment and thus lead to
higher cytotoxicity for the nanocomplx. These factors could lead to the difference of the
two cell lines in the anticancer activity of the nanodrug relative to the free drug.
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3.3.7. Cytotoxicity of MUA-PEG/PTX/Au NRs combined with laser
irradiation.
To examine the capabilities of the nanocomplexes for combined PTT and
chemotherapy, we comparably studied the cytotoxic effects of PTX delivered in DMSO
(chemotherapy without the use of carriers), MUA-PEG/PTX/Au NRs without laser
irradiation (chemotherapy using Au NR carriers), MUA-PEG/PTX/Au NRs with laser
irradiation (combined PTT and chemotherapy) and MUA-PEG/Au NRs plus laser
irradiation (PTT) in both KB and A549 cells. Free PTX is shown to have blood half-life
around 1 h 39. Thus, in these studies, cells were exposed to drugs for 1 h with or without
laser irradiation. Then the cells were washed three times with PBS to remove drugs and
incubated in drug-free medium for 48 h followed by XTT assay. Figure 3.9 shows the
cell viabilities under different treatments at three dosages.
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Figure 3.11. Cytotoxicity of PTX, MUA-PEG/Au NRs with laser irradiation and MUAPEG/PTX/Au NRs with and without laser irradiation in KB-3-1 and A549 cells. Cells
were incubated with PTX-equivalent drug formulations for one hour with or without laser
irradiation, followed by incubation in drug-free medium for 48 h before XTT assay.
Laser irradiation was performed by exposing the cells to NIR light ( = 808 nm) for 10
min at the power density of 0.55 W/cm2. The results are mean values  SD of triplicate
experiments. Combined PTT and chemotherapy with MUA-PEG/PTX/Au NRs showed
excellent anticancer activity, superior to PTT or chemotherapy alone at all drug dosages.
(*P < 0.05 and mean difference > MSD compared with free PTX, MUA-PEG/PTX/Au
NRs, and MUA-PEG/Au NRs plus laser irradiation). Drug concentration was expressed
as equivalent concentration of Au NRs.
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Statistical analysis with ANOVA followed by pair wise comparisons using Scheffe
method showed significant differences (P <0.05, Mean difference  MSD) between the
combination treatment and PTT, chemotherapy with MUA-PEG/PTX/Au NRs or
chemotherapy with free PTX (Table 3.3-3.8).

Table 3.3. ANOVA p-values of A549 and KB-3-1 for four treatments under each
concentration.
Dataset
ANOVA p-value
0.1 nM
0.3 nM
0.5 nM
KB-3-1
1.67E-07
8.10E-09
5.73E-08
A549
2.71E-08
2.73E-09
2.67E-08

Table 3.4. ANOVA p-values of A549 and KB-3-1 for three concentrations under each
treatment.
Dataset

ANOVA p-value
t1

t2

t3

t4

A549

2.57E-06

8.25E-06

2.16E-06

4.27E-05

KB-3-1

1.52E-05

5.11E-05

5.72E-06

7.01E-05

Table 3.5. Pair wise multiple comparisons of KB-3-1 among four treatments by Scheffe
method for each concentration.
0.1 nM

0.3 nM

0.5 nM

KB-3-1

mean
difference

MSD

Sig.

mean
difference

MSD

Sig.

mean
difference

MSD

Sig.

t1 vs t4

13.01

6.64

Yes

8.487

3.03

Yes

8.487

2.62

Yes

t2 vs t4

29.72

6.64

Yes

22.747

3.03

Yes

22.747

2.62

Yes

t3 vs t4

38.31

6.64

Yes

23.627

3.03

Yes

23.627

2.62

Yes

MSD: Minimum Significant Difference
t1: PTX
t2: MUA-PEG/PTX/Au NRs
t3: MUA-PEG/Au NRs + laser
t4: MUA-PEG/PTX/AU NRs + laser
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Table 3.6. Pair wise multiple comparisons of dataset A549 among four treatments by
Scheffe method for each concentration.
0.1 nM
A549
t1 vs t4
t2 vs t4
t3 vs t4

0.3 nM

mean
difference
14.67
34.35
36.74

MSD
5.35
5.35
5.35

0.5 nM

mean
difference
7.67
26.02
17.11

Sig.
Yes
Yes
Yes

MSD
2.61
2.61
2.61

mean
difference
5.55
18.67
10.7

Sig.
Yes
Yes
Yes

MSD
2.44
2.44
2.44

Sig.
Yes
Yes
Yes

MSD: Minimum Significant Difference
t1: PTX
t2: MUA-PEG/PTX/Au NRs
t3: MUA-PEG/Au NRs + laser
t4: MUA-PEG/PTX/AU NRs + laser

Table 3.7. Pair wise multiple comparisons of dataset KB-3-1 among three concentrations
by Scheffe method for each treatment.
t1
KB-3-1
0.1 nM vs
0.3 nM
0.1 nM vs
0.5 nM
0.3 nM vs
0.5 nM

t2

t3

t4

mean
difference

MSD

Sig

mean
difference

MSD

Sig

mean
difference

MSD

Sig

mean
difference

MSD

Sig

8.16

2.85

Yes

10.61

4.89

Yes

18.32

5.67

Yes

3.64

1.85

Yes

13.59

2.85

Yes

18.97

4.89

Yes

31.95

5.67

Yes

6.82

1.85

Yes

5.43

2.85

Yes

8.36

4.89

Yes

13.63

5.67

Yes

3.18

1.85

Yes

MSD: Minimum Significant Difference
t1: PTX
t2: MUA-PEG/PTX/Au NRs
t3: MUA-PEG/Au NRs + laser
t4: MUA-PEG/PTX/AU NRs + laser
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Table 3.8. Pair wise multiple comparisons of dataset A549 among three concentrations
by Scheffe method for each treatment.
t1
A549
0.1 nM vs
0.3 nM
0.1 nM vs
0.5 nM
0.3 nM vs
0.5 nM

t2

t3

t4

mean
difference

MSD

Sig

mean
difference

MSD

Sig

mean
difference

MSD

Sig

mean
difference

MSD

Sig

9.88

2.29

Yes

11.21

3.97

Yes

22.51

4.86

Yes

2.88

1.36

Yes

14.56

2.29

Yes

21.12

3.97

Yes

31.48

4.86

Yes

5.44

1.36

Yes

4.68

2.29

Yes

9.91

3.97

Yes

8.97

4.86

Yes

2.56

1.36

Yes

MSD: Minimum Significant Difference
t1: PTX
t2: MUA-PEG/PTX/Au NRs
t3: MUA-PEG/Au NRs + laser
t4: MUA-PEG/PTX/AU NRs + laser

These differences were reproducible in both cell lines and at multiple dosages. For
example, KB-3-1 cells treated with 0.1 nM MUA-PEG/PTX/Au NRs and 0.1 nM MUAPEG/Au NRs plus laser irradiation, showed cell viabilities of 36.5 and 45.1 %
respectively. However, when these cells were treated with 0.1 nM MUA-PEG/PTX/Au
NRs plus laser irradiation (the combination therapy), cell viability remarkably decreased
to 6.8 %. This combination treatment killed about 30 % more cells than the chemotherapy
and about 40% more cells than the PTT. Similar findings were observed with A549 cells.
The MUA-PEG/PTX/Au NRs showed lower cytotoxicity than the free PTX in
chemotherapy. This is not surprising as only partial PTX can be released within the onehour drug exposure time.
Increasing the concentration of the drug formulations lead to increased cell killing
effects for all treated groups. In the KB-3-1 cell model, viabilities under the
chemotherapy with free PTX, chemotherapy with MUA-PEG/PTX/Au NRs and PTT
with MUA-PEG/Au NRs decreased to 6.2, 17.6 and 13.2 % at 0.5 nM nanocomplex and
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equivalent PTX. No live cells were detected under the combination treatment. Similarly,
cells were completely eradicated under combination treatment for A549 cells while all
other treatment groups showed higher than 5% viabilities. At the 0.5 nM Au NR dosage,
the temperature of the medium with respective to the laser-treated groups was increased
to 58oC. This temperature has been previously demonstrated to induce maximal
photothermal tumor killing without inducing severe tissue bleach and burning in vivo 119.
The 0.1 and 0.3 nM Au NRs raised the temperature of the medium to 43 and 51 oC,
respectively.
Thermal effect of cells could increase membrane permeability, and thus
increasing drug diffusion. It could also change the drug uptake kinetics. These factors
may lead to a synergistic effect between the PTT and chemotherapy, amplifying the
therapeutic outcome dramatically. To determine whether a synergist effect exists in the
combination treatment in our system, cell viability was compared to a purely additive
result. The additive result was calculated according to the following relationship 194
fadditive = fPTT x fchemotherapy

(1)

where fadditive is the fraction of surviving cells by additive interaction of PTT and
chemotherapy, fPTT is the fraction of surviving cells resulting from PTT treatment and
fchemotherapy is the fraction of surviving cells resulting from chemotherapy. When the
fraction of surviving cells from the combination treatment, fcombination is lower than fadditive,
there is a synergistic effect. When fcombination = fadditive, it is an additive effect. The
calculated fadditive for experiments in both cell are listed in Table 3.3.
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Table 3.9. Comparison of calculated fraction of cell survival by additive interaction of
PTT and chemotherapy and experimental value using MUA-PEG/PTX/Au NR.
Cell line

KB-3-1

A549

MUA-PEG/PTX/Au
NR concentration (nM)

Additive cell
viability (% control)

0.1
0.3
0.5
0.1
0.3
0.5

16.4
6.9
2.3
16.8
5.6
2.0

Experimental cell viability
by combined treatment (%
control)
6.8
3.1
0
5.6
2.8
0

The experimental fcombination values of MUA/PTX/Au NRs are lower than the calculated
fadditive values in both KB and A549 cells, regardless of the concentration of the
nanocomplexes. To further examine whether a synergistic effect exist, we compared the
cellular uptake of PTX with and without laser irradiation using A549 cells. Figure 3.10
shows percentage of PTX inside A549 cells (1h-incubation) when the cells were exposed
to 0.1 nM MUA-PEG/PTX/Au NRs, with and without laser irradiation.

70

% PTX inside cells

60
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40
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20
10
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Figure 3.12. Cellular uptake of PTX from MUA-PEG/PTX/Au NRs with and without
laser irradiation. Laser irradiation increased cellular uptake of PTX by ~ 10%.
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Laser irradiation increased cellular uptake of PTX by ~ 10%, which is significantly
different from those without laser irradiation (P = 0.006). Thus, a synergistic effect
existed between PTT and chemotherapy using the MUA-PEG/PTX/Au NRs for
combination cancer therapy.
3.4. CONCLUSION
We have developed a new single particle drug delivery system for PTTchemotherapy of cancer. Hydrophobic PTX was successfully loaded onto NIR-absorbing
Au NRs with high density (2.0 x 104 PTX/Au NR) via a simple, fast and highly efficient
method without pre-modifications of the drug and the carrier. The compact
nanocomplexes were stable under physiological conditions, but efficiently released their
drug payload to exert cytotoxic effects via hydrophobic interactions of the drug and the
apolar lipid membrane. Combined PTT and chemotherapy using the MUA-PEG/PTX/Au
NRs was demonstrated to be synergistic and highly effective, leading to complete
eradication of cultured cancer cells in vitro at a dosage of 0.5 nM nanocomplex with low
intensity (0.55 W/cm2) NIR light. We expect the novel nanocomplex would be able to
deliver high concentration of PTX to tumor sites to eradicate malignant cells
synergistically with PTT. The resulting platform may prevent tumor regrowth and
metastasis and have important impact on the treatment of head and neck cancer and other
malignancies in the clinic.
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Chapter 4. Near-Infrared Absorbing Gold Nanopopcorns with Iron Oxide Cluster
Core for Magnetically Amplified Photothermal and Photodynamic Cancer Therapy

We present the synthesis and application of a new type of dual magnetic and
plasmonic nanostructure for magnetic field-guided drug delivery and combined
photothermal and photodynamic cancer therapy. Near infrared-absorbing gold
nanopopcorns containing self-assembled iron oxide cluster core were prepared via a seedmediated growth method. The hybrid nanostructures are superparamagnetic and show
great photothermal conversion efficiency (= 61%) under near infrared irradiation.
Compact and stable nanocomplexes for photothermal-photodynamic therapy were formed
by coating the nanoparticles with near infrared-absorbing photosensitizer silicon 2,3naphthalocyannie dihydroxide and stabilization with poly(ethylene glycol) linked with
11-mercaptoundecanoic acid. The nanocomplex showed enhanced release and cellular
uptake of the photosensitizer with the use of gradient magnetic field. In vitro studies
using two different cell lines showed that the dual mode photothermal and photodynamic
therapy with the assistance of magnetic field-guided drug delivery dramatically improved
the therapeutic efficacy of cancer cells as compared to the combination treatment without
using magnetic field and the two treatments alone. The “three-in-one” nanocomplex has
the potential to carry therapeutic agents deep into tumor through magnetic manipulation
and to completely eradicate tumors by subsequent photothermal and photodynamic
therapies without systemic toxicity.
4.1. INTRODUCTION
One of the major current interests in nanomedicine is the use of near infrared
(NIR)-absorbing gold (Au) nanoparticles (NPs) for photothermal cancer therapy
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220

. The

rationale is that Au NPs exhibit strong localized surface plasmon resonance (LSPR)
absorption. By changing the particle’s structure or shape, the LSPR wavelength can be
tuned into the tissue-transparent NIR region. Under laser irradiation, the NPs convert
absorbed light quickly (on picosecond time scale) into heat
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that can ablate adjacent

cancer cells. Since the therapeutic mechanism relies on a photophysical process, drug
resistance and systemic toxicity associated with chemotherapy are avoided. During the
past decade, different types of NIR-absorbing Au NPs have been reported and used for
cancer photothermal therapy (PTT), including Au nanoshells,113,114,187 nanorods
(NRs),119,122,189,190 nanocages,124,191 hollow nanospheres,125,192 and recently emerged
nanopopcorns
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and bellflowers.223 Compared to traditional molecular photothermal

agents, these NPs have orders of magnitude higher light absorption efficiency.224 They do
not photobleach and allow for facile surface modification. When coated with
polyethylene glycol (PEG), they show prolonged half-life in blood circulation,182,225
which helps tumor uptake of the NPs and their cargoes through the enhanced
permeability and retention (EPR) effect.
Another light-mediated treatment that uses a chemical mechanism to kill cancer
cells is photodynamic therapy (PDT). In PDT, a photosensitizer (PS) absorbs light energy
and is excited from the ground state to a high energy state which transfers energy to
neighboring oxygen, leading to production of high energy reactive oxygen species (ROS)
(mainly singlet oxygen) to kill cancer cells.226-228 The major problem for traditional PDT
was the target specificity of the PS agents. Substantial efforts have been made to search
for nanocarriers to improve PS delivery.229-232 The use of photothermal NPs as PS carriers
is advantageous over other carriers because cancer cells can be destroyed simultaneously

84

by photothermal and photodynamic therapy under a single laser excitation. Combined
PTT and PDT have been shown more effective than PTT or PDT alone due to additive or
synergistic effects.157,233-242
Here, we report the synthesis and use of a new type of nanoplatform for combined
cancer PTT and PDT. The NPs, which are Au nanopopcorns (NPCs) containing selfassembled iron oxide cluster (IOC) core, which are superparamagnetic and exhibit strong
NIR absorption. Using the IOC-Au NPCs, we demonstrated the first application of
magnetic-optical hybrid nanosystems for magnetic field-guided drug delivery and dual
mode PTT and PDT. Compared to existing PTT and PDT nanosystems, this new system
has the potential to deliver both PDT and PTT agents deep into tumor. It is well known
that tumor penetration of therapeutic agents remains a major issue in drug delivery and
cancer treatment. Previously, Kong et al. reported that magnetic attraction, induced by
gradient magnetic field from a permanent magnet, enhanced the accumulation of
magnetic nanocapsules deep in tumor by 200 fold as compared to that for the control
group
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. This opened new opportunities to deliver therapeutic agents deep into tumor

through magnetic manipulation.
In this work, we effectively integrated the modalities of magnetic field-assisted
drug delivery, PTT and PDT into a single nanoconstruct. We demonstrated through in
vitro studies that combinatorial PTT and PDT with (w/) magnetic attraction is more
effective than PTT and PDT without (w/o) magnetic attraction, PTT or PDT alone. The
PS-loaded IOC-Au hybrid nanoplatform has great potential for highly effective tumor
ablation and may prevent tumor recurrence. The hybrid NPs can also be used as a
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contrast agent for magnetic resonance imaging (MRI) and thus potentially offer a
theranostic platform for tumor detection and therapy.
4.2. MATERIALS AND METHODS
Materials.
All chemicals were purchased from Sigma-Aldrich unless specified. Amineterminated poly (ethylene glycol) (PEG-NH2, MW 5000) was purchased from Laysan Bio
(Arab, AL).
Synthesis and characterization of IO NPs and IOCs.
IO NPs were synthesized by the thermal decomposition method developed by Sun
et al.244 Briefly, iron (III) acetylacetonate (2 mmol), 1,2-hexadecanediol (10 mmol), oleic
acid(6 mmol) and oleylamine (6 mmol) were mixed in 1-octadecene (20 mL) in a threeneck bottle flask. The mixture was heated up to reflux (320°C) under nitrogen
atmosphere for 1 h. After being cooled to room temperature, the resulting solution was
added with ethanol to precipitate the particles. The NPs were concentrated by
centrifugation, washed with hexane, and then resuspended in hexane for further use.
The IOCs were prepared according to our previously reported method with
modifications 245. In this method, 5 mg IO NPs were dried under argon and mixed with
10 mg N-alkyl polyethylenimine(PEI) 2k in 500 L of chloroform. The mixed solutions
were added into 5 mL of distilled under sonication. Then, the mixture was shaken for
overnight and the chloroform was removed by rotary evaporation to obtain PEI-coated
IOCs. The PEI-coated IOCs were dispersed in water for further use. The N-alkyl-PEI 2k
was prepared in advance by reacting 1-iodododecane with PEI2k in ethanol at 55oC for 6
h, followed by solvent evaporation and purification with dialysis.
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Synthesis and characterization of IOC-Au NPCs.
The PEI-coated IOCs were initially coated with a layer of negatively charged
polymer to reverse the surface charge for subsequent growth of the Au layer. This was
done by mixing the clusters (0.2 mg/mL, Fe concentration in this paper) with polystyrene
chloride (PSS, 20 mg/mL) in the presence of 20 mM sodium hydroxide for 30 min. After
purification by magnetic separation, the PSS/PEI-coated IOCs were dispersed in water
and used as seeds to make IOC-Au NPCs based on a seed-mediated growth method with
modifications 179. Firstly, the PSS/PEI-coated IOCs (0.5 mL, 0.2 mg/mL) were adsorbed
with diamminesilver ions (Ag(NH3)2+) (20 L, 10 mM), followed by reduction with
sodium borohydride (NaBH4) (100 L, 10 mM) to form Ag-decorated IOCs. The Agdecorated IOCs were purified by centrifugation and redispersed in ultrapure water to
form the seed solution (0.5 mL, 0.2 mg/mL). In a separate glass flask, 45 mL of gold
growth solution containing 0.1 M cetyl trimethylammonium bromide (CTAB), 0.4 mM
chloroauric acid (HAuCl4) and 80 M AgNO3 was prepared and heated to 25oC in a
water bath, followed by addition of 0.69 mL of 40 mM ascorbic acid (AA) to reduce
HAuCl4 to HAuCl2. Then, 150 L of the seed solution was injected and IOC-Au hybrid
NPs formed within 2 h. The NPs were purified by 2 times of centrifugation and washing
with ultrapure water. The absorption spectrum of the NPs was measured using an Ocean
Optics UV-VIS-NIR absorption spectrometer (Dunedin, FL). The size and morphology of
the NPs were examined with a JEOL JEM-1200 EXII electron transmission microscope
(TEM). Size distribution was calculated from about 150 NPs. Chemical components of
the nanostructures were determined using Energy Dispersive X-Ray Spectroscopy (EDX)
on a Nova NanoSEM 650 Field emission scanning electron microscope (FE-SEM). The
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magnetic properties were measured using a vibration sample magnetometer (Dexing
Magnets, China). Magnetic separation was performed using a Qiagen 12-tube magnet
with the surface field around 4000 G.
Determination of photothermal conversion efficiency of IOC-Au NPCs.
The photothermal conversion efficiency of the NPs was measured according to
the method reported previously. 246,247 Specifically, 200 L of 3.2 g/mL IOC-Au
NPCs (OD808 = 1) in a 1.7 mL centrifuge vial was irradiated with a 808 nm diode
laser (Power technologies, Little Rock, AR). The diameter of the laser beam was 1 cm
and the power density was 0.55 W/cm2. A thermocouple was inserted into the solution
to record the temperature. The temperature was monitored during both heating (laser
on) and cooling (laser off) stages. The photothermal conversion efficiency  was
calculated using the following equation
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(1)
where h is the heat transfer coefficient, S is the surface area of the container, Tmax is
the maximum equilibrium temperature, Tamb is the ambient temperature of the
surroundings, Qdis is a parameter expressing the laser- induced heat input by the
container, I is the laser power, and A808 is the absorbance of the NPs at 808 nm. The
same experiment was conducted with water as the control to determine Qdis (mW) by:
Qdis=103mCT/t
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(2)

Where m is the mass of water (g), C is the heat capacity of water (Jg-1K-1), T is the
increased temperature (K), and t is the laser exposure time (s). The term hS was
calculated based on
(3)
where s is the sample system time constant and i is the system components (NP
suspension and sample container). s is related to a dimensionless driving force
temperature  by
t = -s ln

(4)

where t is the cooling time and  is given by
 = (T-Tamb)/( Tmax-Tamb)

(5)

PS Loading and Stabilization on IOC-Au NPCs.
PS loading and stabilization on the IOC-Au NPCs were performed by adapting
our previously reported method 248 Firstly, 11-mercaptoundecanoic acid-linked PEG
(MUA-PEG) was synthesized as the stabilization agent. This was done through a N,Ndicyclohexylcarbodiimide (DCC)-activated coupling reaction between PEG-NH2 and
MUA in anhydrous dichloromethane (DCM). The polymer was purified by centrifugal
filtration. To load PS onto IOC-Au NPCs, 1 mL of 4.0 g/mL IOC-Au NPCs were mixed
with silicon 2,3-naphthalocyannie dihydroxide (SiNC) at various concentrations (0.05 to
4 M) for 15 min. Then, 250 L of 1 mM MUA-PEG was added and the solution was
stirred for another 45 min. The MUA-PEG/SiNC/IOC-Au NPCs were purified by three
rounds of centrifugation (12,000 rpm, 10 min) and washing with ultrapure water. The
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residue was reconstituted with ultrapure water. The nanocomplex with saturated SiNC
coating was used for further studies.
The stability of SiNC-loaded IOC-Au NPCs in phosphate buffered saline (PBS),
cell culture medium and serum.
MUA-PEG/SiNC/IOC-Au NPCs were dispersed in 1x PBS (pH 7.4, 137 mM
NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4 and 1.47 mM KH2PO4), RPMI 1640 cell culture
medium (Mediatech, Inc., Manassas, VA) with 10% fetal bovine serum (FBS, Gemini
Bio-Products, West Sacramento, CA) or 100% FBS to make 1 mL of 4 g/mL solution.
The solution was shaken on an orbital shaker (600 rpm) to mimic blood circulation. At a
specified time from 30 to 360 min, 200 L of the solution was withdrawn and
centrifuged. The supernatant was collected and mixed with equal volume of DCM and
stirred vigorously for 4 h. Then, the DCM layer was collected and the solvent was
evaporated. The residue was reconstituted and concentrated with 20 L of DMSO. SiNC
was quantified by Raman spectroscopy using a portable Raman spectrometer (Enwave
Optronics, Inc., Irvine, CA).

SiNC release from IOC-Au NPCs w/ and w/o magnetic attraction under cellular
environment.
KB-3-1 head and neck cancer cells were cultured in RPMI 1640 medium
supplemented with 10% (v/v) FBS and pencilium-streptomycin solution (100 U/mL
penicillin, 100 U/mL streptomycine) at 37oC under 5% CO2. The cells were seeded at a
density of 8 x 103 cells per well into 96-well plates in triplicate. After 24 h, the medium
was replaced with 100 L of fresh medium containing 4 g/mL MUA-PEG/SiNC/IOC90

Au NPCs. After a specified time from 30 to 360 min, the cell culture medium was
collected. SiNC in the medium were extracted with DCM, followed by solvent
evaporation and resuspension with DMSO. SiNC was quantified by Raman spectroscopy.
SiNC released was expressed as the percentage of SiNC inside cells compared to the total
amount of SiNC from the added MUA-PEG/SiNC/IOC-Au NPCs. The same experiment
was performed in the presence of magnetic field, in which a permanent neodymium–
iron–boron (NdFeB) block magnet (4"x4"x2"thick, surface field: ~4900 G) was placed
under the 96-plate during incubation. To ensure the similar field for each well, only the
cell wells located within 2"x2" area of the magnet were used.
Laser irradiation, magnetic attraction and cell viability assay.
KB-3-1 and SK-BR-3 (breast cancer) cells were seeded at a density of 8 x 103
cells per well into 96-well plates in triplicate. After 24 h, the medium was replaced with
100 L of fresh medium containing the following formulations: (1) SiNC (DMSO as the
solvent), (2) MUA-PEG/IOC-Au NPCs, (3) MUA-PEG/SiNC/IOC-Au NPCs, and (4)
MUA-PEG/SiNC/IOC-Au NPCs w/NdFeB block magnet. Cells w/o any treatment were
used as the control. The laser treatment, 10 min irradiation with a 808 nm diode laser
(Beam size: 8 mm. Power intensity: 0.55 W/cm2) (Power Technologies, Little Rock, AR)
was conducted 2 h after the addition of the formulations. After laser irradiation, cells
were washed with PBS and incubated in drug-free medium for overnight. The effect of
dosage on cell killing efficiency was examined by using different concentrations of the
nanocomplex from 1 to 4 g/mL. Free drug was added at an equivalent concentration of
SiNC in the nanocomplex. Cell viability was determined using the XTT toxicology
assay. The cell viability was expressed as the percentage of live cells over that of the
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untreated control. The data are presented as the mean  standard deviation of triplicate
measurements.
Statistical analysis.
The statistical significance of the cell viabilities under different treatments and
different concentrations were compared using the analysis of variance (ANOVA). A pvalue < 0.05 was considered statistically significant in all cases. Multiple comparison
procedures were used after obtaining a significant ANOVA result. A post hoc Scheffe
method was applied to determine which means differed. The mean difference between
treatments or concentrations was considered to be significant if the absolute value was
greater than the minimum significant difference (MSD) that was derived from the Scheffe
method.
4.3. RESULTS AND DISCUSSION
4.3.1. Synthesis and characterization of IOC-Au NPCs.
NIR-absorbing Au NPs with IO core have been previously made by several
research groups including our group 179,249-258. In these studies, single IO NPs were used
as the core materials. It will be highly desirable to make the hybrid NPs with IOC core.
This is because IOCs show better magnetic properties compared to the individual IO NPs
as each cluster is composed of many individual particles. For example, research has
shown that IOCs (~ 100 nm in diameter) show 2 times higher T2 relaxivity coefficients
than the individual IO NPs (~ 9 nm in diameter),259 making them excellent contrast
agents for magnetic resonance imaging (MRI).
Oleic acid-coated IO NPs were prepared by the classic thermal decomposition
method 244. The NPs were about 8 ± 1.3 nm (mean ± SD) in diameter (Figure 4.1A&D).
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The IOCs were prepared by self-assembly of the IO NPs with alkyl-PEI2K. The low
molecular weight amphiphilic polymer transfers hydrophobic IO NPs from organic
solvent to aqueous phase while holding multiple particles together to form clustered
structures. The diameter of the IOCs was 87 ± 11 nm (Figure 4.1B&E). The clusters were
well dispersed in water and stable up to 6 months at room temperature.
In order to grow Au on the IOCs, the clusters were coated with PSS by
electrostatic adsorption to introduce negative charge through the sulfonate groups. These
negatively charged groups were used as the anchor points to adsorb Ag(NH3)2+ ions that
were subsequently reduced to form small Ag NPs (2-5 nm) as the nucleation sites for the
growth of Au shell. PSS coating was confirmed by DLS characterization (Table 4.1). The
PSS-coated IOCs showed a surface potential of -19.8 mV, in contrast to the highly
positive charge of the PEI-coated clusters (43.2 mV).

Table 4.1. Characterization of the preparation of IOC-Au NPCs by dynamic light
scattering method.
Hydrodynamic Diameter Zeta Potential
(nm)
(mV)
IOCs
95 ± 2.3
43.2 ± 1.4
PSS/IOCs
112 ± 2.7
-19.8 ± 0.9
IOC-Au NPCs
170.4 ± 3.4
27.4 ± 1.3

The formation of IOC-Au NPs was initiated by injection of the Ag-adsorbed IOCs
into a reduced Au growth solution containing HAuCl2, CTAB, AgNO3 and AA. Such a
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growth solution has been widely used to make metal NPs in various shapes by fine
control of the concentration of the chemical components 260,261. The formation of various
shapes is the outcome of the interplay between the faceting binding tendency of the
stabilizing agent CTAB and the growth kinetics 260 Preparation of anisotropic
nanostructures is desirable because anisotropic NPs are known to give better electric field
enhancement than the spherical ones,180 a phenomenon that enhances many optical
activities such as surface enhanced Raman scattering (SERS). In our studies, we made
IOC-Au NPCs with the reduced growth solution consisting of 0.4 mM HAuCl2, 0.1 M
CTAB, 80 M AgNO3 and 1.2 mM AA. The IOC-Au NPCs were 158 ± 18 nm (Figure
4.1C&F). Considering the thickness of the PSS layer (~10 nm determined by DLS), the
average thickness of the external Au structure was about 30 nm.
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Figure 4.1. Structural characterization of IO NPs (A&D), IOCs (B&E) and IOC-Au
NPCs (C&F). (A, B, & C) TEM images. (D, E, & F) Size distribution calculated from
~150 NPs. The average size of the IO NPs, IOCs, and IOC-Au NPCs was 8, 87 and 157
nm, respectively.
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The IOC-Au NPCs absorb in the NIR region, with a broad LSPR peak around 800
nm (Figure 4.2A). They are superparamagnetic, with a saturation magnetization around
22 emu/g (Figure 4.2B). This value is approximately one-half of that of the IOCs, due to
the mass contribution from the diamagnetic Au that has 4-fold higher density than the IO.
The magnetic property was further confirmed by their separation in the presence of a
magnetic field. The IOC-Au NPCs were separated from the solution within 2 h when the
sample was attached to a permanent magnet, similar to the IOCs (Figure 4.2C). This
demonstrates that the IOC-Au NPCs are indeed core-shell NPs. The EDX spectrum
reveals the presence of both Fe and Au (Figure 4.2D). The relative intensities of the Au
and Fe peaks indicate that the particles are largely of Au character. In addition, Au has a
much higher atomic weight than Fe, which also contributes to the strong signals from Au.
The peak at 8 Kev is from Cu on the support TEM grid.
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Figure 4.2. Optical absorption and magnetic properties of IOC-Au NPCs. (A) Absorption
spectrum of IOC-Au NPCs. (B) Room temperature magnetization curves of IOCs and
IOC-Au NPCs. (C) Photographs of the magnetic separation of IOCs and IOC-Au NPCs.
(D) EDX spectrum of IOC-Au NPCs.
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To understand the growth mechanism of the hybrid NPs, we examined the effects
of particle formation by the amount of Au precursor in the growth solution. This was
done by injecting different amounts of the Ag-decorated IOC seed. The results showed
that when the amount of the seed was high (relative amount of Au precursor per seed
particle is low), individual Au NPs on the IOCs were clearly seen (Figure 4.3A). When
the amount of seed was decreased, the individual Au NPs grew larger and adjacent Au
NPs coalesced by the deposition of Au onto the NPs from solution (Figure 4.3B-D). The
LSPR band red shifted in wavelength and increased in intensity (Figure 4.3F). When the
amount of the seed was further decreased, IOC-Au NPs with protrudent Au structures
formed, resulting in IOC-Au NPCs (Figure 4.3E).
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Figure 4.3. Morphology (A-E) and of absorption spectra (F) of IOC-Au NPCs with
different amount of IOC seed amount during preparation. (A) 40 L, (B) 30 L, (C) 20
L, (D) 10 L, and (E) 5 L. (F) Increasing absorption intensity with a decrease in
amount of seed added indicated more gold was present on the IOCs.
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HRTEM image of individual NPs (Figure 4.4) revealed that the Au grew along the (111)
direction.

Figure 4.4. HRTEM images of individual IO-Au NPCs. The results show that the Au
grew in the (111) direction.
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4.3.2. Photothermal performance of the IOC-Au NPCs.
To investigate the potential capability of the IOC-Au NPCs for photothermal
therapy, the photothermal conversion efficiency, , of the particles was determined. In
these studies, the temperature of a NP solution under continuous laser irradiation and
subsequent cooling with laser being turned off was recorded. The cooling process was
used to determine the rate of heat transfer from the NP solution to the environment.
Figure 4.5A shows the plot of the temperature versus time for an aqueous IOC-Au NPC
sample (OD=1.0) during the laser heating and cooling processes. The temperature
increased by 40 oC when the NP solution was irradiated for 320 s and did not change
significantly with further irradiation. The temperature reached a maximum because of the
equilibrium between the heat input and output. In contrast, the temperature of the control
water increased by only 0.9 oC (Figure 4.5B). Using the equation (2) and the heating
profile of the water, the Qdis was determined to be 1.57 mW. Figure 4.5C shows the plot
of the cooling time t versus the term -ln θ. The data shows a linear relationship, giving a
slope of 110.6 s, the s. Using the equation (3), the term hS was calculated to be 7.6
mW/oC. Based on equation (1), the efficiency of transducing the red laser to heat by the
IOC-Au NPCs was calculated to be 61%.
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Figure 4.5. Photothermal property of IOC-Au NPCs. (A) Plot of the temperature versus
time for the IO-Au NPCs (4.0 g/mL, OD808= 1.0) during laser irradiation (808 nm, 0.55
W/cm2) and cooling (laser off). The temperature increased from an ambient value of
21.4oC to an equilibrium value of 62.0oC during continuous irradiation for 600 s. (B) Plot
of temperature versus time for the water during laser irradiation (808 nm, 0.55 W/cm2).
(C) Plot of the cooling time versus –Ln. Based on the linear regression analysis, the time
constant for heat transfer τs (the slope of the plot) was determined to be 110 s.
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For comparison, we made Au NRs, one of the well-known NIR-absorbing Au
nanostructures in PTT. The NRs have an average aspect ratio of 4.1, with length around
45 nm and width around 11 nm (Figure 4.6A). The NRs have the LSPR around 795 nm,
largely overlapping with the NIR laser wavelength at 808 nm (Figure 4.6B). Figure 4.6C
shows the plot of the temperature versus time for an aqueous Au NRs sample
(OD808=1.0) during the laser heating and cooling processes. The plot of the cooling time,
t, versus the term -ln θ is shown in Figure 4.6D. Based on this information and equations
(1) to (5), we determined that the photothermal conversion efficiency of Au NRs is 75%,
which is higher than that of IO-Au NPCs.
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Figure 4.6. Gold NR characterization. (A) TEM image of gold nanorods. (B) Absorption
spectrum of gold nanorods. Red line shows the position of laser source. (C) Plot of the
temperature versus time for gold nanorods (OD808= 1.0) during laser irradiation (808 nm,
0.55 W/cm2) and cooling (laser off). The temperature increased by 49oC during
continuous irradiation for 600 s. (D) Plot of the cooling time versus –Ln. Based on the
linear regression analysis, the time constant for heat transfer, τs, was determined to be
108 s.
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This is not surprising because photothermal conversion efficiency is largely dependent on
the particle’s volume, shape and structure as well as the overlapping of the LSPR of the
NPs with the laser wavelength 262. Chen and co-workers recently reported that Au
bellflowers around 150 nm show a photothermal conversion efficiency of 74% in the NIR
region 223. For NPs with similar shape and structure, larger NPs have stronger light
scattering contribution in the total extinction efficiency and thus may give lower
photothermal conversion efficiencies than smaller NPs. It is worth to mention that other
researchers have reported different photothermal conversion efficiencies of Au NRs (24%
246

, 60% 263 and 90% 262) depending on the dimension of the NRs and the laser source

used. Under our experimental conditions, Au NRs show higher photothermal conversion
efficiency and correspondingly work better than IO-Au NPCs in PTT. However, Au NRs
do not have magnetic properties. The IO-Au hybrid NPCs have the advantage of
combined optical and magnetic properties and thus offer new capabilites in biomedical
diagnostics and treatment.
4.3.3. Preparation and characterization of SiNC-loaded IOC-Au NPCs.
To achieve deep light penetration into tissue, ideal PS agent should absorb light in
the NIR region. They should also have good singlet oxygen quantum yield (0.2) to
ensure sufficient efficacy. Hydrophobic sensitizers are generally more effective than
hydrophilic ones in cells and tumor uptake with a similar yield of singlet oxygen 264. We
chose SiNC as the PS agents. SiNC is one of the dye-based hydrophobic PS molecules. It
has strong absorption in the NIR window, with the absorption maxima at 778 nm in
DMSO (Figure 4.7). In a more hydrophilic environment (3 DMSO: 1 water), the
absorption maxima is red shifted to 795 nm, which overlaps well with the irradiation
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laser wavelength (808 nm). The SiNC has a good singlet oxygen quantum yield
(=0.35),265 comparable to that of the clinically used phthalocyanine (PC)-based
molecules that has only marginal NIR absorption 219.
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Figure 4.7. Structure (insert) and absorption spectra of SiNC. The absorption maximum
is 778 nm in DMSO and 795 nm in DMSO/water.

We have previously demonstrated that hydrophobic drug can be loaded onto Au
nanorods through the interaction of the drug with the hydrophobic interior of the CTAB
capping bilayer on the surface of the nanorods 248. CTAB was then replaced with
amphiphilic MUA-PEG without displacing the drug molecules. The drug was entrapped
in the hydrophobic interior of the MUA-PEG monolayer. Using the same method, we
loaded SiNC onto IOC-Au NPCs and stabilized the SiNC-adsorbed particles with MUAPEG. The SiNC adsorption was characterized by SERS measurement. The MUAPEG/SiNC/IOC-Au NPCs gave strong Raman signals from SiNC, indicating successful
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SiNC adsorption (Figure 4.8A). The signal intensity increased with the increase of the
SiNC concentration, reaching a maximum around 1 M due to saturated adsorption
(Figure 4.8B). Assuming all SiNC was adsorbed at this condition, the loading efficiency
was 19.4% (mass of SiNC/mass of Fe). Subsequent MUA-PEG binding was examined by
DLS measurement.
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Figure 4.8. Characterization of SiNC loading onto IOC-Au NPCs by SERS spectroscopy.
(A) SERS spectra of MUA-PEG/SiNC/IOC-Au NPCs at different SiNC loading
concentrations. (B) Plot of SERS signal intensity at 685 cm-1 versus the SiNC loading
concentration. Excitation laser wavelength: 785 nm. Laser power: 25 mW. Acquisition
time: 1 s.
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Table 4.2 showed that the as-prepared IOC-Au NPCs had the hydrodynamic
diameter (HD) of 170 nm and zeta potential () of +27 mV. The highly positive surface
charge is due to the positively charged CTAB capping materials. When the particles were
modified with MUA-PEG (w/ or w/o SiNC), the HD of the NPCs increased by 20 nm and
the  decreased by 35 mV. These changes indicate the successfully replacement of CTAB
by MUA-PEG on the surface of the particles.

Table 4.2. Characterization of SiNC loading onto IOC-Au NPCs by dynamic light
scattering method.
HD (nm)
 (mV)
IOC-Au NPCs
170.4± 3.4
27 ±1.3
MUA-PEG/IOC-Au NPCs
189.7±2.8
-7.2±0.8
MUA-PEG/SiNC/IOC-Au NPCs 190.2±2.7
-7.8±1.0

4.3.4. Stability and drug release profile of MUA-PEG/SiNC/IOC-Au NPCs.
The stability of the nanocomplex was examined in PBS, cell culture medium and
100% serum. To mimic blood circulation, the nanocomplexes in the above solutions were
continuously shaken on an orbit shaker. At different times, an aliquot of the solution was
centrifuged and the supernatant was extracted with DCM to determine the amount of
SiNC released from the nanocomplex. SiNC was quantified via the calibration plot
obtained from Raman spectroscopy (Figure 4.9B). Although SiNC gave weaker Raman
signals than those adsorbed on the particles, quantization of SiNC can be achieved at
elevated laser power and acquisition time (Figure 4.9A).
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Figure 4.9. (A) Raman spectrum of SiNC at different molar concentrations. (B) Plot of
signal intensity at 685 cm-1 versus the concentration of SiNC. Laser wavelength: 785 nm.
Laser power: 250 mW, Acquisition time: 10 s.

Figure 4.10A shows that less than 2% of SiNC was released after 1 h in all the solutions.
After 6 h, less than 8% of SiNC was released in all cases. These results demonstrate that
the MUA-PEG/SiNC/IOC-Au NPCs have excellent stability in the physiological
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environments. The SiNC release property was studied under a cellular environment. In
this study, we incubated SK-BR-3 cells with cell culture medium containing MUAPEG/SiNC/IOC-Au NPCs. After a specified time, we determined the amount of SiNC
remaining in the medium. We assumed that all the SiNC released from the nanocomplex
entered cells. Figure 4.10B (black) shows that the nanocomplex exhibits a biphasic drug
release profile with the rapid release process occurring within the first two hours. Then,
SiNC release slowly increased, with 78% of SiNC released at 5 h. These studies
demonstrate that SiNC release from the MUA-PEG/SiNC/IOC-Au NPCs is highly
efficient upon exposure to live cells. The release is due to the preferential localization of
hydrophobic drugs to the cell lipid membrane.
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Figure 4.10. Stability (A) and drug release profile (B) of MUA-PEG/SiNC/IOC-Au
NPCs. Drug release in (B) were determined under cellular environment.

A similar study was performed in the presence of a magnetic field. In this
experiment, a permanent magnet (surface field ~4900 G) was placed under the 96-well
plate during the incubation. Figure 4.10B (red) shows that the SiNC release profile w/
magnetic field is similar to those w/o magnetic field. However, the release efficiency at
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each examined time point is relatively higher. For examples, at 30 min, while 37% SiNC
was released from the nanocomplex w/o magnetic field, 52% SiNC was released w/
magnetic field. At 2 h, SiNC release was 65% and 81% for w/o and w/ magnetic field,
respectively. This indicates that magnetic field significantly accelerated the release of
SiNC. This is because the magnetic field facilitates the movement of the magnetic
nanocomplex toward the cell membrane. With further incubation (10 h), however, the
amount of SiNC released w/ magnetic field is only slightly higher that w/o magnetic
field. This is not surprising since the majority of loaded SiNC has been released within 10
h. It is realized that under in vivo conditions, magnetic attraction will not only accelerate
SiNC release, but also enhance deep penetration of the nanocarrier and the cargos.37
4.3.5. Photothermal-photodynamic therapy w/ and w/o magnetic fieldassisted drug delivery.
To examine the capabilities of the nanocomplexes for dual mode PTT and PDT as
well as the effect of magnetic field-guided drug delivery on the therapeutic efficacy, we
comparably studied the cytotoxic effects of PTT, PDT, PTT + PDT, PTT + PDT +
magnetic attraction using MUA-PEG/IOC-Au NPCs, SiNC, MUA-PEG/SiNC/IOC-Au
NPCs, and MUA-PEG/SiNC/IOC-Au NPCs w/magnetic attraction, respectively. In these
studies, cells were incubated with the above drug formulations for 2 h and then subjected
to laser irradiation for 10 min. The concentration of SiNC used for the PDT treatment in
each dose was determined based on the SiNC loading efficiency and the release
efficiency at 2h w/o magnet (see Figure 6). For these samples with magnetic field, the
magnet was placed under the cell culture before the addition of drug formulations and
remained under the plates during the whole course of experiments. After laser treatment
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(10 min, 0.55 W/cm2), the cells were washed three times with PBS to remove drugs and
then incubated in drug-free medium for overnight before the XTT assay. The studies were
carried out using two different cell lines KB-3-1 and SK-BR-3 under three different doses
1, 2, and 4 g/mL nanocomplex or free SiNC with equivalent concentrations.
Figure 4.11 shows the cell viabilities under different treatments at three doses.
Statistical analysis with ANOVA followed by pair wise comparisons using Scheffe
method showed significant differences (P <0.05, Mean difference  MSD) between the
different groups (Table 4.3-8). These differences were reproducible in both cell lines and
at multiple dosages.
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Figure 4.11. Comparison of the efficacy of PTT + PDT + magnetic attraction against
KB-3-1 (A) and SK-BR-3 (B) cells to that of PTT, PDT, and PTT + PDT. PTT, PDT and
PDT+PTT were achieved using MUA-PEG/IOC-Au NPCs, SiNC, and MUAPEG/SiNC/IOC-Au NPCs, respectively. The results are mean values  SD of triplicate
experiments. (*P < 0.05 as compared to PTT, PDT, and PTT+PDT).
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For example, when the KB-3-1 cells were treated with a low concentration (1
g/mL) of MUA-PEG/IO-Au NPCs and laser irradiation (PTT), 49.1 % cells remained
alive. When the cells were treated with equivalent concentration of SiNC (0.19 g/mL)
and laser irradiation (PDT), 70.9% cells remained alive. However, when the cells were
treated with 1 g/mL MUA-PEG/SiNC/IO-Au NPCs and laser irradiation (PTT+PDT),
the cell viability was reduced to 26.3%. The cell viability was further reduced to 7.1%
with the use of magnetic attraction. These results showed that the combination treatment
killed 23 % more cells than PTT and 45% more cells than PDT. Using magnetic
attraction, the combination treatment killed 42% more cells than PTT and 64% more cells
than PDT. The enhanced efficacy with the use of magnetic attraction is attributed to the
increased amount of PDT inside the cells, as shown in Figure 6B. It is worthy to mention
that the temperature of the medium was only raised to 42-45oC when PTT was involved.
These studies demonstrate that combined PTT and PDT using MUA-PEG/SiNC/IO-Au
NPCs are much more effective than PTT or PDT alone. The magnetic attraction further
amplified the combination treatment at a large degree, due to increased cellular uptake of
the PS agents as the field facilitated the movement of the nanocomplex toward cell
membrane.
Increasing the concentration of the drug formulations led to increased cell killing
for all treatment groups. For the combination group, the cell viability was decreased to
11.1 % at 2 g/mL and 1.2 % at 4 g/mL MUA-PEG/SiNC/IO-Au NPCs in KB-3-1 cells.
A similar trend was observed in SK-BR-3 cells. When the magnetic field was used, all
KB-3-1 cells were killed at both 2 and 4 g/mL MUA-PEG/SiNC/IO-Au NPCs and all
SK-BR-3 cells were killed at 4 g/mL MUA-PEG/SiNC/IO-Au NPCs. The temperature
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of the medium in the presence of 2 and 4 g/mL MUA-PEG/SiNC/IO-Au NPCs was
raised to 55 and 62oC, respectively. These studies demonstrate that highly efficient cell
killing can be achieved with low dose of drug formulations ( 4 g(Fe)/mL) and low
intensity of laser (0.55 W/cm2) under the combinatorial PTT and PDT with the assistance
of magnetic field-guided drug delivery using the MUA-PEG/SiNC/IO-Au NPC complex.

Table 4.3. ANOVA p-values of SK-Br-3 and KB-3-1 for four treatments under each
concentration.
Dataset
ANOVA p-value
1 g/mL
2 g/mL
4 g/mL
KB-3-1
4.38E-13
2.39E-15
3.16E-11
SK-BR-3
7.52E-13
1.35E-12
2.67E-11

Table 4.4. ANOVA p-values of SK-Br-3 and KB-3-1 for three concentrations under each
treatment.
Dataset
ANOVA p-value
t1
t2
t3
t4
KB-3-1
6.78E-08
1.85E-08
6.05E-10
2.24E-07
SK-Br-3
3.45E-07
1.72E-10
3.20E-09
3.03E-08
t1: SiNC
t2: MUA-PEG/IOC-Au NPCs
t3: MUA-PEG/SiNC/IOC-Au NPCs
t4: MUA-PEG/SiNC/IOC-Au NPCs + magnet
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Table 4.5. Pair wise multiple comparisons of KB-3-1 among four treatments by Scheffe
method for each concentration.
1 g/mL

2 g/mL

4 g/mL

KB-3-1

mean
difference

MSD

Sig.

mean
difference

MSD

Sig.

mean
difference

t1 vs t4

63.52

5.42

Yes

52.34

2.98

Yes

30.78

t2 vs t4

42.86

5.42

Yes

35.70

2.98

Yes

21.90

4.28

Yes

t3 vs t4

19.47

5.42

Yes

11.75

2.98

Yes

1.49

4.28

No

t1 vs t3

44.05

5.42

Yes

40.58

2.98

Yes

29.29

4.28

Yes

t2 vs t3

23.39

5.42

Yes

23.95

2.98

Yes

20.40

4.28

Yes

t1 vs t2

20.66

5.42

Yes

16.64

2.98

Yes

8.88

4.28

Yes

MSD

Sig.

4.28

Yes

MSD: Minimum Significant Difference
t1: SiNC
t2: MUA-PEG/IOC-Au NPCs
t3: MUA-PEG/SiNC/IOC-Au NPCs
t4: MUA-PEG/SiNC/IOC-Au NPCs + magnet

Table 4.6. Pair wise multiple comparisons of dataset SK-Br-3 among four treatments by
Scheffe method for each concentration.
1 g/mL
SK-Br3

mean
difference

t1 vs t4

50.59

t2 vs t4

2 g/mL

MSD

Sig.

mean
difference

Yes

48.33

36.02

4.46
4.46

Yes

t3 vs t4

19.86

4.46

t1 vs t3

30.72

4.46

t2 vs t3

16.15

4.46

t1 vs t2

14.57

4.46

4 g/mL

MSD

Sig.

mean
difference

MSD

Sig.

Yes

30.39

3.89

Yes

31.04

4.59
4.59

Yes

19.45

3.89

Yes

Yes

11.78

4.59

Yes

4.05

3.89

Yes

Yes

36.56

4.59

Yes

26.34

3.89

Yes

Yes

19.26

4.59

Yes

15.40

3.89

Yes

Yes

17.29

4.59

Yes

10.94

3.89

Yes

MSD: Minimum Significant Difference
t1: SiNC
t2: MUA-PEG/IOC-Au NPCs
t3: MUA-PEG/SiNC/IOC-Au NPCs
t4: MUA-PEG/SiNC/IOC-Au NPCs + magnet
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Table 4.7. Pair wise multiple comparisons of dataset KB-3-1 among three concentrations
by Scheffe method for each treatment.
t1
KB 3-1
1 vs 2
g/mL
1 vs 4
g/mL
2 vs 4
g/mL

t2

t3

t4

mean
difference

MSD

Sig

mean
difference

MSD

Sig

mean
difference

MSD

Sig

mean
difference

MSD

Sig

18.22

6.27

Yes

14.20

3.80

Yes

14.76

2.32

Yes

7.04

1.47

Yes

39.78

6.27

Yes

28.00

3.80

Yes

25.02

2.32

Yes

7.04

1.47

Yes

21.56

6.27

Yes

13.80

3.80

Yes

10.27

2.32

Yes

0

1.47

No

MSD: Minimum Significant Difference
t1: SiNC
t2: MUA-PEG/IOC-Au NPCs
t3: MUA-PEG/SiNC/IOC-Au NPCs
t4: MUA-PEG/SiNC/IOC-Au NPCs + magnet

Table 4.8. Pair wise multiple comparisons of dataset SK-BR-3 among three
concentrations by Scheffe method for each treatment.
t1

SK-Br-3
1 vs 2
g/mL
1 vs 4
g/mL
2 vs 4
g/mL

t2

t3

t4

mean
difference

MSD

Sig

mean
difference

MSD

Sig

mean
difference

MSD

Sig

mean
difference

MSD

Sig

19.43

6.34

Yes

16.54

2.38

Yes

19.65

3.28

Yes

11.56

2.05

Yes

32.25

6.34

Yes

29.62

2.38

Yes

28.86

3.28

Yes

13.05

2.05

Yes

13.81

6.34

Yes

13.08

2.38

Yes

9.22

3.28

Yes

1.49

2.05

No

MSD: Minimum Significant Difference
t1: SiNC
t2: MUA-PEG/IOC-Au NPCs
t3: MUA-PEG/SiNC/IOC-Au NPCs
t4: MUA-PEG/SiNC/IOC-Au NPCs + magnet
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4.3.6. Synergistic effects of combination treatment.
Thermal effect could increase cell membrane permeability, and thus increasing
drug diffusion. It could also change the drug uptake kinetics. These factors may lead to a
synergistic effect between PTT and PDT, amplifying the therapeutic outcome. To
determine whether a synergist effect exists in the combination treatment in our system,
cell viability was compared to a purely additive result from PTT and PDT. The additive
result was calculated according to the following relationship 194
fadditive = fPTT x fPDT

(6)

where fadditive is the fraction of surviving cells by additive interaction of PTT and PDT,
fPTT is the fraction of surviving cells resulting from PTT treatment and fPDT is the fraction
of surviving cells resulting from PDT. When the fraction of surviving cells from the
combination treatment, fcombination, is lower than fadditive, there is a synergistic effect
between the two treatments. When fcombination = fadditive, there is an additive effect. When
fcombination is larger than fadditive, there is an antagonistic effect. The calculated fadditive in
both cell lines are listed in Table 4.9. The results showed that the fcombination of PTT and
PTT was significantly lower than the calculated fadditive in KB-3-1 cells in all three doses,
indicating a synergist effect between PTT and PDT in this cell line. However, no
significant difference between fcombination and fadditive of PDT and PTT was observed in the
SK-BR-3 cells, indicating an additive effects between these two treatments in this cell
line. The PTT + PDT + magnetic attraction gave lower fcombination values than those from
PTT + PDT, due to the increased concentration of SiNC inside cells via the magnetic
attraction.
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Table 4.9. Comparison of calculated fadditive from PDT and PTT with experimental
fcombination for PTT+PDT and PTT+PDT+magnetic attraction.
[MUA-PEG/SiNC
Cell line
fadditive
fcombination
fcombination

KB-3-1

SK-BR-3

IO-Au NPC]
(g(Fe)/mL)

(PTT+PDT)

(PTT + PDT)

1
2
4
1
2
4

34.7%
19.0%
7.3%
30.7%
16.0%
5.7%

26.3%
11.1%
1.2%
33.5%
13.5%
4.5%

(PTT+PDT+
magnetic attraction)

7.1%
0.0%
0.0%
13.5%
1.6%
0.0%

4.4. CONCLUSION
We have synthesized popcorn-shaped dual functional iron oxide-gold
nanostructures and demonstrated their capability for magnetic field-guided drug delivery
and combinatorial PTT and PDT for cancer. The hybrid nanostructures were prepared via
seed-mediated growth of Au onto self-assembled IO clusters. They are superparamagnetic
and NIR-responsive, with excellent photothermal conversion efficiency. A stable and
compact nanocomplex for dual PTT and PDT was formed using the hybrid
nanostructures as the PS carriers and PT agents, NIR-absorbing SiNC as the PS agents,
and MUA-PEG as the stabilization agents. PS release and intracellular uptake was
enhanced by applying a magnetic field. Combined PTT and PDT in conjunction with
magnetic field-assisted drug delivery using the nanocomplex was demonstrated to be
highly effective, leading to complete eradication of cultured cancer cells in vitro at a dose
of 2 g(Fe)/mL nanocomplex for KB-3-1 cells and 4 g(Fe)/mL for SK-BR-3 cells with
low intensity of NIR light (0.55 W/cm2). We expect that the novel nanocomplex will be
able to deliver high concentration of PS molecules and the nanocarriers deep into tumor
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tissue via applying a magnetic field on the surface of tumors. The high concentration
therapeutic agents, together with the excellent photothermal conversion efficiency of the
hybrid nanostructures, would lead to highly effective tumor ablation via combined PTT
and PDT. The all-in-one nanoplatform may prevent tumor regrowth and metastasis and
have an important impact on the treatment of head and neck cancer, breast cancer and
other malignancies.
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Chapter 5. Conclusions and Outlook
The work in this dissertation focused on two areas: In Chapter 2 circulating tumor
cell capture and detection was studied. In Chapters 3 and 4, improvement of current
cancer therapies was examined with the use of multifunctional nanocomplexes. In
Chapter 2 we developed superparamagnetic, compact IO-Au core-shell NPs in oval
shapes having a SPR around 590 nm by using 7 times lower concentration of ascorbic
acid than those used for making IO-Au nanopins in our previous studies 179 (
Figure 2.). The nanoovals (NOVs) were coated with 1.2 x 104 QSY21 per particle and
conjugated with anti-EpCAM and anti-HER2 antibodies (Figure 2.2). The conjugated
nanoprobes were successfully formed by incubating SK-BR-3 cells in 1 mL of PBS with
anti-EpCAM/QSY21/IO-Au NPs and anti-HER2/QSY21/IO-Au NPs and characterized
with DLS (Table 1). The conjugated NPs showed specific binding to SK-BR-3 cells
(Figure 2.4). The on-line system was built by integrating a syringe pump with two NdFeB
magnets (K&J Magnetics Inc) and a portable Enwave Raman spectrometer. The optimal
flow velocity for magnet 1 was determined to be 6 cm/s, which gave 90% capture
efficiency of pre-labeled cancer cells and 2% of free NPs (Figure 2.5A). The optimal
flow velocity for magnet 2 was determined to be 0.2 cm/s, which gave 100% capture
efficiency of pre-labeled cancer cells (Figure 2.5B). Using the on-line system, we have
determined that IO-Au SERS NPs targeting EpCAM and HER2 allowed magnetic
capture of CTC-mimic SK-BR-3 cells and subsequent SERS detection on-line, with a
LOD of 1-2 cells/mL blood (Figure 2.8).
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In Chapter 3 we developed a therapeutic method for photothermal-chemotherapy
of cancer by loading hyrdophobic paclitaxel (PTX) onto NIR absorbing Au NRs with a
SPR at 800nm (Figure 3.1). PTX was successfully loaded onto the Au NRs with a high
density (2.0 x 104 PTX/Au NR). The nanocomplex was characterized by DLS at each
step (Table 3.1). In order to increase the hydrophobic pocket for drug loading and also
increase blood circulation time, MUA-PEG was successfully synthesized with a yield of
~ 71%. The polymer was characterized by NMR and UV-vis (Figure 3.3 & 3.5). The
nanocomplexes showed excellent stability under physiological conditions, while
efficiently releasing their drug payload to exert cytotoxic effects via hydrophobic
interactions of the drug and the apolar lipid membrane (Figure 3.6 & 3.7). The
cytotoxicity of the nanocomplex was studied in two cancer cell lines, head and neck (KB3-1) and lung cancer (A549). We compared the cytotoxicity of PTX alone
(chemotherapy), MUA-PEG/PTX/Au NRs without laser irradiation (chemotherapy using
Au NR carriers), MUA-PEG/PTX/Au NRs with laser irradiation (combined PTT +
chemotherapy) and MUA-PEG/Au NRs plus laser irradiation (PTT). Figure 3.9
demonstrates the MUA-PEG/PTX/Au NRs (with laser irradiation) ability to completely
eradicate cancer cells in vitro at a dose of 0.5 nM. Figure 3.10 further showed that the
combinatorial treatment had a synergistic effect as laser irradiation of the multifunctional
nanocomplex increased cellular uptake of PTX by ~ 10%.. After concluding our studies,
we expect the novel nanocomplex would be able to deliver high concentration of PTX to
tumor sites to eradicate malignant cells synergistically with PTT thus reducing current
toxicity to normal cells associated with paclitaxel chemotherapy. The resulting platform
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may prevent tumor regrowth and metastasis and have an important impact on the
treatment of head and neck cancer and other malignancies in the clinic.
In Chapter 4 we developed a novel nanocomplex and studied their capabilities for
magnetic-field-guided drug delivery and combinatorial photothermal (PTT) and
photodynamic therapy (PDT) of cancer. We have synthesized iron oxide cluster-gold
nanopopcorns (IOC-Au-NPCs) with a strong SPR absorption around 800 nm and
excellent magnetic properties (Figure 4.2). The IOC-Au NPCs showed great potential as
a photothermal agent with a photothermal conversion efficiency () of 61% (Figure 4.5).
This is comparable to Au NRs (75%), which has been the standard NP for PTT (Figure
4.6). We loaded silicon 2,3 napthalocyanine dihydroxide (SiNC) onto the IOC-Au NPCs
via a similar method used to load paclitaxel onto Au NRs as discussed in Chapter 2. We
characterized the nanocomplex size and zeta potential at each step using DLS.(Table 4.2).
The stability of the nanocomplex was examined in various media and showed excellent
stability in physiological environments with less than 2% of PS released after 1 hr.
(Figure 4.10 ). Figure 4.10 also showed PS release and intracellular uptake was
accelerated by applying an external magnetic field. We studied the therapeutic effect of
the nanocomplex by comparing SiNC (PDT), MUA-PEG/IOC-Au NPCs (PTT), MUAPEG/SiNC/IOC-Au NPCs (PTT+PDT), -PEG/SiNC/IOC-Au NPCs w/magnetic attraction
(PTT+PDT + magnetic assistance) (Figure 4.11). We found that combined PTT and PDT
along with magnetic field-assisted PS delivery demonstrated the highest efficacy, leading
to complete eradication of cultured cancer cells in vitro at a dose of 2 g(Fe)/mL
nanocomplex for KB-3-1 cells and 4 g(Fe)/mL for SK-BR-3 cells with low intensity of
NIR light (0.55 W/cm2). The results have led us to believe the novel nanocomplex will be
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able to more efficiently deliver the PS loaded NPs deep into tumor tissue via applying a
magnetic field on the surface of tumors. This will allow a lower dose of the PS which in
turn would lead to less cytotoxicity of normal cells. The nanocomplex offers the distinct
advantage of using a single laser source for combined PDT+PTT which will lead to more
effective tumor ablation and may prevent tumor regrowth and metastasis. The multimodal
nanocomplex may have an important impact clinical impact on the treatment of head and
neck cancer, breast cancer and other malignancies.
Future Perspective.
In Chapter 2, we demonstrated the great potential of IO-Au SERS nanoprobes for
dual capture and highly sensitive detection of circulating tumor mimic cells spiked in
whole blood without tedious sample preparations and complex techniques. The current
research opens a new opportunity for developing next generation technology for the
detection of rare cells. Although demonstrating the systems capabilities, the method can
still be further improved. First, multiplexed targeting can be readily achieved to further
increase the detection sensitivity and specificity of CTCs. A major challenge in CTC
detection is molecular recognition. This is because CTCs include a heterogeneous
population of cells with diverse molecular characteristics. Multiplexed IO-Au NOVs can
be readily formed using different targeting ligands without changing the size and
structure of the NPs. Thus, CTCs with different molecular markers can be simultaneously
isolated and captured, followed by direct detection with SERS technology without use of
additional probes. Second, multiplexed detection can be achieved for molecular profiling
of biomarker expression using the same nanostructures. This can be done by simply
changing the Raman tags. In addition, the on-line flow system can be readily translated
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into a microfluidic device for automated, rapid and point-of-care detection. Furthermore,
a Raman microscope can be used for automated detection of CTCs at single cell
resolution and for molecular profiling of biomarker expressions on single cells. The
above improvement in the near future would lead to a new generation of technology for
highly automated and rapid detection and molecular profiling of CTCs in for use in
clinical settings with high sensitivity and specificity. The new platform will make a major
impact in cancer diagnosis and prognosis and ultimately aid in the treatment for patients
with breast cancer and other malignancies.
In Chapters 3 and 4 we studied the therapeutic potential of drug loaded NIR
absorbing NPs for combination treatment of cancer. The studies showed great potential in
eradicating cancer cells and proved to be more effective versus traditional cancer
treatments available. The next step will be to examine the therapeutic effect of the novel
nanocomplexes in vivo before reaching the ultimate goal of using the nanocomplexes in a
clinical setting to increase the overall survival rate of cancer patients.
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